Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof

ABSTRACT

A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described.

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority to co-pending U.S. Provisional Application No. 61/448,702 filed on Mar. 3, 2011, the contents of the application is hereby incorporated by reference herein for all purposes.

GOVERNMENT RIGHTS IN INVENTION

This invention was made with government support under Grant Number GM080374 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to glycoprotein synthesis, and more particularly, to the synthesis of structure defined core-fucosylated glycopeptides wherein one or more oligosaccharide sugar chains with a predetermined number of sugar moieties are added to a α-1,6-fucosylated N-acetylglucosamine (GlcNAc)-containing peptide or protein to form core-fucosylated glycopeptides and glycoproteins.

2. Description of the Related Art

Glycosylation is a remarkable strategy taken by nature to expand the biological information of a relatively concise human genome. The oligosaccharide components of glycoproteins not only affect protein's structure and stability, but also directly participate in many molecular recognition processes such as cell adhesion, differentiation, tumor metastasis, and host-pathogen interactions [1-6]. Ample examples have shown that subtle changes in the glycan structures of glycoproteins can result in significant differences in functions [7-11]. Core fucosylation, that being, the attachment of an α-1,6-linked fucose to the innermost GlcNAc moiety of asparagine (N)-linked glycans, is a natural modification frequently found in natural and mammalian cell line-expressed N-glycoproteins.

It has been shown that core fucosylation affects N-glycan conformations and regulates the interactions between N-glycans and glycan-binding proteins including various lectins [12-14, 19]. For example, the presence of core fucose on IgG antibody's Fc glycans significantly impacts the binding of the Fc domain to the Fc γIIIa receptor on a cell surface and which is responsible for antibody-dependent cellular cytotoxicity (ADCC) [8, 15-17]. After the antibody's recognition and binding to a target cell, ADCC and other effector functions are triggered through the binding of the antibody's Fc region to receptors. More and more evidence have shown that different glycosylation forms can exert significantly different effects on the properties of a given therapeutic antibody, some sugar chains are beneficial, while others are detrimental.

A typical immunoglobulin G (IgG) antibody is composed of two light and two heavy chains that are associated with each other to form three major domains connected through a flexible hinge region: the two identical antigen-binding (Fab) regions and the constant (Fc) region. It is noted that there are heterogeneous glycosylation states of the human IgG when expressed in mammalian cell lines (e.g., CHO cell lines), and isolation of human IgG having a particular glycosylation state from this mixture is extremely difficult. Small amounts of impurities of a highly active species can dramatically interfere with the results and data interpretation. Generation of high-affinity mAbs to Fc receptors, such as the Fc γIIIa receptor, may overcome the problem of polymorphism of the Fcγ receptor variants, thus enhancing the clinical efficacy of therapeutic mAbs. Additionally, it was reported that core-fucosylation increased significantly for some cancer cells, suggesting that core-fucosylated N-glycans and/or glycoproteins could serve as novel biomarkers for diagnosis [18-21].

Notably, functional glycomics studies aiming to understand the detailed structure-function relationships of glycosylation are often hampered by the difficulties to obtain structurally well-defined complex oligosaccharides and glycoconjugates either from natural sources or from synthesis. The past two decades have witnessed a remarkable advance in synthetic method development for making homogeneous glycopeptides and glycoproteins [22-36]. Nevertheless, chemical and chemoenzymatic synthesis of sialylated and fucosylated complex glycopeptides or glycoproteins is still a challenging task, because of the labile nature of α-sialyl/α-fucosyl glycosidic linkages during synthetic manipulations [29, 37, 38]. Late-stage enzymatic introduction of the core fucose by α-1,6-fucosyltransferase (Fut8) does not seem to be feasible because Fut-8 only accepts the truncated N-glycan core as a substitute for α-1,6-fucosylation and does not recognize sialylated and/or galactosylated N-glycan substrates.

Transglycosylation by endo-α-N-acetylglucosaminidases (ENGases), a class of endoglycosidases that inherently cleave N-glycans from glycoproteins, have recently been explored for glycopeptide synthesis and glycosylation remodeling of glycoproteins [39-56]. Two GH family 85 ENGases, the Endo-A from Arthrobacter protophormiae and the Endo-M from Mucor hiemalis, have been particularly useful for native ligation between a pre-assembled oligosaccharide oxazoline and a GlcNAc-peptide/protein to form a homogeneous glycopeptide or glycoprotein in a regio- and stereo-specific manner without the need of any protecting groups. Thus, this chemoenzymatic method is highly convergent and permits independent synthetic manipulations of the glycan and polypeptide portions. Recently, this method has been extended to the synthesis of sialylated complex glycopeptides and sialylated ribonuclease C [56]. However, to this date, the discussed chemoenzymatic method was not feasible for the synthesis of core-fucosylated glycopeptides. As such, so far there were no reports of any endoglycosidases capable of transferring oligosaccharides to core-fucosylated GlcNAc acceptor.

As such, there is a need for proper and consistent glycosylation in developing core-fucosylated glycopeptides and glycoproteins to be used for development and production of therapeutic agents while reducing negative effects such as allergy problems or undesired immune responses and conferring significant and consistent stability and activity.

SUMMARY OF THE INVENTION

The present invention relates to the synthesis of fucosylated glycopeptides or glycoproteins wherein a desired sugar chain is added to a fucosylated GlcNAc-protein acceptor by transglycosylation to form structure defined core-fucosylated glycopeptides or glycoproteins. As such, the present invention allows for the synthesis and remodeling of therapeutic glycopeptide or glycoprotein drugs, glycoprotein hormones, cytokines, therapeutic antibodies thereby providing for certain activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.

In one aspect, the present invention provides for novel transglycosylation activity of Flavobacterium meningosepticum endoglycosidases, that being, Endo-F1, Endo-F2, Endo-F3 and mutants thereof, wherein the mutants have 95% homology thereto and exhibit the transglycosylation activity on fucosylated GlcNAc acceptors, wherein the endoglycosidases enable the transfer of an oligosaccharide (in the form of an activated sugar oxazoline) en bloc to a fucosylated GlcNAc-peptide acceptor to form a core-fucosylated glycopeptide. The transglycosylation activity of Endo-F1 (SEQ ID No: 1), Endo-F2 (SEQ ID No: 2), Endo-F3 (SEQ ID No: 3), Endo D and mutants thereof is specific for fucosylated GlcNAc acceptors, as transglycosylation activity on non-fucosylated GlcNAc acceptors is not detected under the same reaction conditions, such as in a buffer, pH 7 and at room temperature. Mutants preferably include site-specific mutations at active carboxyl residues that promotes product hydrolysis, including but not limited to, mutations at Asp-130 (SEQ ID NO: 10) of Endo-F1, mutations at Asp-124 of Endo-F2 (SEQ ID NOs: 4 and 5) mutations at Asp-126 of Endo-F3 (SEQ ID NOs: 6 and 7) and mutation at Asn-322 of Endo-D (SEQ ID NO: 8 and 9).

Sequences from Endo-F1, Endo-F2, and Endo-F3, as shown in FIG. 20, show remarkably enhanced transglycosylation efficiency due to the diminished or abrogated product hydrolytic activity. Mutations at “D” highlighted in FIG. 20 (D130 in Endo-F1, D124 in Endo-F2 and D126 in Endo-F3) in the respective sequences provide for active sites for such mutations and having the ability to use the activated glycan oxazolines as donor substrates for transglycosylation. For example, in Endo-F3, the following mutants, having at least 95% identity to Endo-F3, are effective for transglycosylation including but not limited to D126R, D126N, D126C, D126E, D126G, D126H, D126I, D126L, D126K, D126M, D126F, D126P, D126S, D126T, D126W, D126Y, and D126V.

In another aspect, the present invention provides efficient mutants of Endo-D, an endo-β-N-acetylglucosaminidase from Streptococcus pneumonia, for transglycosylation with glycan oxazolines. The Endo-D mutants, including but not limited to, N322A (SEQ ID NO: 8) and N322Q (SEQ ID NO: 9), show remarkably enhanced transglycosylation to either fucosylated or non-fucosylated GlcNAc acceptor.

In a further aspect, the present invention provides for a chemoenzymatic method for the preparation of a homogeneous fucosylated glycoprotein or glycopeptide, comprising:

-   -   (a) providing an acceptor selected from the group consisting of         a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and     -   (b) reacting the acceptor with a donor substrate including an         activated oligosaccharide moiety, in the presence of an         endoglycosidase (ENGase) selected from Endo-F1, Endo-F2,         Endo-F3, Endo-D or mutants thereof to transfer the activated         oligosaccharide moiety to the acceptor and yield the homogeneous         fucosylated glycoprotein or glycopeptide.

In a still further aspect, the present invention provides a method for preparing a core-fucosylated glycoprotein or glycopeptide having a predetermined oligosaccharide moiety, comprising:

-   -   (a) providing a core-fucosylated acceptor glycoprotein or         glycopeptide comprising an asparagine-linked N-acetylglucosamine         (GlcNAc) residue linked to a core fucose residue; and     -   (b) enzymatically reacting the core-fucosylated acceptor         glycoprotein or glycopeptide with an activated oligosaccharide         donor in the presence of at least one endoglycosidase selected         from Endoglycosidase-F2 (SEQ ID NO: 2 or a sequence having 95%         homology thereto), Endoglycosidase-F2 D124A (SEQ ID NO: 4) or         D124Q (SEQ ID NO:5) mutant, Endoglycosidase-F3 (SEQ ID NO: 3 or         a sequence having 95% homology thereof), Endoglycosidase-F3         D126A (SEQ ID NO: 6) or D126Q (SEQ ID NO: 7) mutant, and         Endoglycosidase-D N322Q (SEQ ID NO: 9) mutant, wherein the         activated oligosaccharide donor carries an oligosaccharide         moiety comprising a predetermined number and type of sugar         residues, such that, via enzymatic reaction, the oligosaccharide         moiety is covalently linked to the acceptor glycoprotein or         glycopeptide; thereby preparing the core-fucosylated         glycoprotein or glycopeptide having the predetermined         oligosaccharide moiety.

Notably, the wild type Endo-D amino acid sequence can also be defined without the signal peptide sequence included in the numbering and such a sequence is defined in SEQ ID NO: 15, wherein the mutation is N282A (SEQ ID NO: 16) or N282Q (SEQ ID NO: 17).

In yet another aspect, the present invention provides for an activated oligosaccharide moiety, such as glycosyl fluoride, glycosyl azide or an aryl glycoside, as a donor substrate for the synthesis of homogeneous core-fucosylated glycopeptides or glycoproteins. Preferably the activated oligosaccharide moiety is an oligosaccharide oxazoline.

In a further aspect, the present invention relates to a chemoenzymatic method for the preparation of a homogeneous fucosylated glycopeptide or glycoprotein, said method comprising:

-   -   (a) providing an acceptor selected from fucosylated glycopeptide         or glycoprotein comprising a fucosylated GlcNAc containing         peptide or protein; and     -   (b) reacting the acceptor with a donor substrate in the presence         of an endoglycosidase (ENGase) selected from Endo-F1, Endo-F2,         Endo-F1 Endo-F3, Endo-D and/or mutants thereof, wherein the         donor substrate comprises a predetermined oligosaccharide         component with a defined number and type of sugar residues and         specific linkage types, thereby providing the homogeneous         fucosylated glycopeptide or glycoprotein.

The fucosylated GlcNAc containing peptide or protein is preferably an alpha-1-6-fucosyl-GlcNAc-peptide or an alpha-1-6-fucosyl-GlcNAc-protein.

In another aspect, the invention relates to a method of fucosylated glycopeptide or glycoprotein remodeling with an oligosaccharide having a predetermined oligosaccharide component with a defined number and type of sugar residues and with specific linkage types, the method comprising:

-   -   (a) providing a fucosylated glycopeptide or glycoprotein         substrate comprising at least two GlcNAc residues;     -   (b) treating the fucosylated glycopeptide or glycoprotein         substrate with an endo-enzyme to hydrolyze the bond between the         two GlcNAc residues positioned closest to the peptide thereby         forming a fucosylated glycopeptide or glycoprotein substrate         with a single GlcNAc-moiety; and     -   (c) attaching the oligosaccharide to the single GlcNAc moiety in         the presence of an endoglycosidase selected from the group         consisting of Endo-F1, Endo-F2 and Endo-F3, thereby adding a         predetermined the oligosaccharide component.

In a further aspect, the invention relates to a method of fucosylated glycopeptide or glycoprotein remodeling with an oligosaccharide having a predetermined oligosaccharide component with a defined number and type of sugar residues and with specific linkage types, the method comprising:

-   -   (a) providing a fucosylated glycopeptide or glycoprotein         obtained from natural or recombined sources carrying         heterogeneous N-glycans;     -   (b) treating the fucosylated glycopeptide or glycoprotein         substrate with an endo-enzyme (a wild type endoglycosidase or a         mutant endoglycosidase with efficient hydrolytic activity) to         hydrolyze the bond between the two GlcNAc residues positioned         closest to the peptide thereby forming a deglycosylated peptide         or protein carrying the fucosylated GlcNAc disaccharide moiety         at the original glycosylation site(s); and     -   (c) attaching the pre-determined oligosaccharide to the GlcNAc         residue in the fucosylated GlcNAc disaccharide moiety to         reconstitute the natural α-1,4-glycosidic bond through the         transglycosylation with an endoglycosidase selected from         Endo-F1, Endo-F2, Endo-F3, Endo-D, and/or their glycosythase         mutants, thereby adding a predetermined the oligosaccharide         component.

Applicable oligosaccharide oxazolines include, but not limited to, high-mannose type, hybrid type, and complex type N-glycan, as well as their selectively modified derivatives. Preferably, di-, tri-, tetra-, penta-, hexyl-, hepta-, octyl-, nona-, deca-, or undeca-saccharide oxazolines are utilized as donor substrates for a highly efficient chemoenzymatic synthesis of homogeneous core-fucosylated glycopeptides or glycoproteins.

In yet another aspect, the present invention relates to a method of synthesis of a modified antibody or fragment thereof, the method comprising;

-   -   (a) using a naturally existing IgG antibody or a recombinant         antibody or Fc domains carrying Fc N-glycans as precursors;     -   (b) Fc deglycosylating using an endoglycosidase such as Endo-F2,         Endo-F3, or, Endo-S, Endo-D, or their hydrolytic         activity-enhanced mutants to deglycosylate the Fc domain;     -   (c) providing an antibody comprising at least one fucosylated         GlcNAc moiety to form a fucosylated GlcNAc-acceptor; wherein the         fucosylated GlcNAc moiety is positioned on the Fc region of the         antibody; and     -   (d) transglycosylating the fucosylated GlcNAc moiety in the         antibody with an oligosaccharide oxazoline having a         predetermined number of sugar residues under the catalysis of an         enzyme selected from the group consisting of Endo-F1, Endo-F2,         Endo-F3, Endo-D or their mutants thereof to form the modified         antibody with the predetermined number of saccharides.

In a still further aspect, the invention relates to a method of synthesizing homogeneous fucosylated glycopeptide or glycoprotein, the method comprising:

-   -   (a) providing a heterogeneous fucosylated glycopeptide or         glycoprotein comprising different high mannose type N-glycans,         wherein the heterogeneous fucosylated glycopeptide or         glycoprotein is from a natural source or produced from a wild         type or engineered yeast system;     -   (b) removing the different high mannose type N-glycans by an         enzyme selected from the group consisting of Endo-H, Endo-S and         Endo-A to form a fucosylated GlcNAc-containing peptide or         protein;     -   (c) providing a sugar containing oxazolines with a desired         oligosaccharide component comprising a defined number and type         of sugar residues in the chain; and     -   (d) enzymatically transglycosylating, with an endoglycosidase         selected from the group consisting of Endo-F1, Endo-F2, Endo-F3,         Endo-D and mutants thereof, the fucosylated GlcNAc-containing         peptide or protein with the sugar containing oxazoline thereby         forming a homogeneous fucosylated glycopeptide or glycoprotein         having an extension of desired number of sugar residues.

In another aspect, the present invention relates to a method of synthesis of a modified antibody or fragment thereof, the method comprising;

-   -   (a) providing an antibody comprising at least one fucosylated         GlcNAc moiety to form a fucosylated GlcNAc-peptide acceptor;         wherein the fucosylated GlcNAc moiety is positioned on the Fc         region of the antibody; and     -   (b) transglycosylating an oligosaccharide oxazoline having a         predetermined number of saccharides and the fucosylated         GlcNAc-peptide acceptor under the catalysis of an enzyme         selected from the group consisting of Endo-F1, Endo-F2, Endo-F3,         Endo-D or their mutants thereof to form the modified antibody         with the predetermined number of saccharides.

It is envisioned that the oligosaccharide oxazoline having a predetermined oligosaccharide component with a defined number and type of sugar residues may further comprises an additional moiety or tag including, a therapeutic agent or drug such as for treating cancer, HIV or other viruses, substances that activates receptors on the cell plasma membrane, agents that affects intracellular chemistry, agents that affects cellular physics, genes, gene analogs, RNA, RNA analogs, DNA, DNA analogs, amino acid sequences of surface receptors such as CCR5 or CD4, antigenic structure having affinity for a specific antibody; amino acid sequences of receptor ligands such as gp120, gp41 or gp160, receptor antagonists, receptor blockers, enzymes, enzyme substrates, enzyme inhibitors, enzyme modulators, therapeutic proteins, protein analogs, metabolites, metabolite analogs, oligonucleotides, oligonucleotide analogs, antigens, antigen analogs, antibodies or fragments thereof, antibody analogs, an antibody different from the modified antibody which is reactive to another receptor bacteria, viruses, inorganic ions, metal ions, metal clusters, polymers, fluorescent compounds and any combinations thereof.

As such, the present invention further provides a delivery device for delivering a drug having biological activity to treat a condition, the delivery device comprising: a remodeled fucosylated glycoprotein or glycopeptides having a predetermined sugar chain and a therapeutic agent or drug attached to the terminal sugar residue.

The present invention envisions modifying monoclonal antibodies related to HIV including, but not limited to 17b, 48d, A32, C11, 2G12, F240, IgG1b12, 19e, X5, TNX-355 and F91, all of which are commercially available. Further antibodies related to cancer or other diseases may also be remodeled for individual fit to certain receptors thereby increasing biological activity, the monoclonal antibodies may include, but are not limited to, cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101 (Aphton), volociximab (Biogen Idec and PDL BioPharm), Anti-CD80 mAb (Biogen Idec), Anti-CD23 mAb (Biogen Idel), CAT-3888 (Cambridge Antibody Technology), CDP-791 (Imclone), eraptuzumab (Immunomedics), MDX-010 (Medarex and BMS), MDX-060 (Medarex), MDX-070 (Medarex), matuzumab (Merck), CP-675,206 (Pfizer), CAL (Roche), SGN-30 (Seattle Genetics), zanolimumab (Serono and Genmab), adecatumumab (Sereno), oregovomab (United Therapeutics), nimotuzumab (YM Bioscience), ABT-874 (Abbott Laboratories), denosumab (Amgen), AM 108 (Amgen), AMG 714 (Amgen), fontolizumab (Biogen Idec and PDL BioPharm), daclizumab (Biogent Idec and PDL BioPharm), golimumab (Centocor and Schering-Plough), CNTO 1275 (Centocor), ocrelizumab (Genetech and Roche), HuMax-CD20 (Genmab), belimumab (HGS and GSK), epratuzumab (Immunomedics), MLN1202 (Millennium Pharmaceuticals), visilizumab (PDL BioPharm), tocilizumab (Roche), ocrerlizumab (Roche), certolizumab pegol (UCB, formerly Celltech), eculizumab (Alexion Pharmaceuticals), pexelizumab (Alexion Pharmaceuticals and Procter & Gamble), abciximab (Centocor), ranibizimumab (Genetech), mepolizumab (GSK), TNX-355 (Tanox), or MYO-029 (Wyeth).

A still further aspect of the invention relates to a method of remodeling an antibody which initially includes a heterogeneous sugar chain, including polyclonal and monoclonal antibodies, the method comprising:

-   -   (a) removing the heterogeneous sugar chain from the antibody         with an endoglycosidase to leave a single fucosylated-GlcNAc         moiety attached to an original glycosylation site; and     -   (b) transferring a core oligosaccharide with at least one tag to         the fucosylated-GlcNAc moiety by an endoglycosidase catalyzed         transglycosylation to yield a tagged antibody, wherein the         endoglycosidase is selected from the group consisting of         Endo-F1, Endo-F2, Endo-F3, Endo-D and mutants thereof.

The tag moiety may include, but is not limited to, antigens, therapeutic drugs such as for cancer or HIV, toxins, fluorescent probes, biotin, PEG species, lipids, or nucleotides.

In another aspect, the present invention provides for a method of treatment using a remodeled antibody having a desired glycosylation state in an amount sufficient to modulate biological activity in the treated subject.

Other aspects, features and embodiments of the invention will be more fully apparent from the ensuing disclosure and appended claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the synthesis of Fmoc-Asn(Fucα1,6GlcNAc)-OH (9).

FIG. 2 shows the screening transglycosylation activity using the Fmoc-Asn(Fucα1,6GlcNAc)-OH (9) as the acceptor and synthetic sugar oxazolines (10 and 12) as the donor substrates.

FIG. 3 shows the time courses of endoglycosidases-catalyzed transglycosylation on Fmoc-Asn(Fucα1,6GlcNAc)-OH (9) monitored by HPLC. Panel A: Man₃GlcNAc oxazoline (10) as the donor substrate; Panel B: sialoglycan oxazoline (12) as the donor substrate.

FIG. 4 shows the HPLC monitoring of the transglycosylation reaction between oxazoline 10 and acceptor 9 in the presence of Endo-F3. a) 0 min; b) 30 min; c) 60 min; and d) 120 min. The identity of the peaks was confirmed by ESI-MS analysis: S, acceptor 9; P, transglycosylation product 11; and H, Man3GlcNAc, (the hydrolysis product of oxazoline 10).

FIG. 5 shows the screening transglycosylation activity using non-fucosylated GlcNAc-Asn-Fmoc (14) as the acceptor and Man₃GlcNAc oxazolines (10) as the donor substrate.

FIG. 6 shows the HPLC-monitored time courses of Endoglycosidases-catalyzed transglycosylation on Fmoc-Asn(GlcNAc)-OH using Man₃GlcNAc oxazoline as the donor substrate.

FIG. 7 shows the chemoenzymatic synthesis of a sialylated and core-fucosylated CD52 antigen.

FIG. 8 shows the ¹H NMR spectrum of Fucα1,6GlcNAc-CD52 (17).

FIG. 9 shows the ¹H-¹H 2D COSY NMR spectrum of Fucα1,6GlcNAc-CD52 (17).

FIG. 10 shows the 1H-¹³C 2D HSQC NMR spectrum of Fucα1,6GlcNAc-CD52 (17).

FIG. 11 shows a scheme for PNGase F digestion of CD52 glycoprotein (18).

FIG. 12 shows a scheme for Endo-F3 digestion of CD52 glycoprotein (18).

FIG. 13 shows the ¹H-¹³C 2D HSQC NMR spectrum of the core-fucosylated complex type CD52 (18).

FIG. 14 shows the ¹H NMR spectrum of the core-fucosylated complex type CD52 (18).

FIG. 15 shows the ¹H-¹H 2D COSY NMR spectrum of the core-fucosylated complex type CD52 (18).

FIG. 16 shows the structure of a typical monoclonal antibody and the Fc N-glycans.

FIG. 17 shows the synthesis or remodeling of core-fucosylated glycopeptides and glycoproteins.

FIG. 18 shows the glycosylation remodeling of monoclonal antibodies.

FIG. 19 shows the glycosylation remodeling of a recombinant IgG-Fc.

FIG. 20 shows the sequence and alignment of the three endo-beta-N-acetylglucosaminidases (Endo-F1 (SEQ ID NO: 1), Endo-F2 (SEQ ID NO: 2), and Endo-F3 (SEQ ID NO: 3) from Flavobacterium meningosepticum (alternative name; Elizabethkingia meningosepticum) [85].

FIG. 21 shows the sequence of the endo-beta-N-acetylglucosaminidase from Streptococcus pneumonia (Endo-D) (SEQ ID NO: 11) [86].

FIG. 22 shows the time courses of the transglycosylation of the fucosylated GlcNAc acceptor (9) with sialoglycan oxazoline (12) of FIG. 2 under the catalysis of glycosynthase mutant, Endo-F3 D126A.

FIG. 23 shows the transglycosylation remodeling of IgG-Fc through transglycosylation with Endo-D mutants.

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology, microbiology, cell biology and recombinant DNA, which are within the skill of the art. See, e.g., Sambrook, et al. MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R. I. Freshney, ed. (1987)).

DEFINITIONS

As used in the specification herein, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more.

As used herein, “biological activity” refers to pharmacodynamic and pharmacokinetic properties including, for example, molecular affinity or resultant biochemical or physiological effect, receptor affinity or resultant biochemical or physiological effect, non-receptor affinity or biochemical or physiological effect, efficacy, bioavailability, absorption, distribution, metabolism, or elimination.

As used herein, “sugar” refers to an oxidized or unoxidized carbohydrate-containing molecule, including, but not limited to, a monosaccharide, disaccharide, trisaccharide, oligosaccharide, or polysaccharide, including, for example, N-acetylglucosamine, mannose, galactose, N-acetylneuraminic acid (sialic acid), glucose, fructose, fucose, sorbose, rhamnose, mannoheptulose, N-acetylgalactosamine, dihydroxyacetone, xylose, xylulose, arabinose, glyceraldehyde, sucrose, lactose, maltose, trehalose, cellobiose or any combination thereof of the L- or D-isomer. Sugar further refers to, such molecules produced naturally, recombinantly, synthetically, and/or semi-synthetically.

As used herein, “homogenous” refers to core-fucosylated glycopeptides or glycoproteins wherein the oligosaccharide component comprises at least 75%, more preferably at least 90%, and most preferably at least 95% of the same number and types of sugar residues.

As used herein, “homology” refers to amino acid sequence having substantial identity or similarity between two polypeptides and having at least 90%, and more preferably at least 95% similarity to a reference polypeptide. For polypeptides, the length of comparison to obtain the above-described percent homologies between sequences will generally be at least 25 amino acids, alternatively at least 50 amino acids, more likely at least 100 amino acids, and most likely 200 amino acids or more. Substantially identity or homologous polypeptides include additions, truncations, internal deletions or insertions, conservative and non-conservative substitutions, or other modifications located at positions of the amino acid sequence which do not destroy the function of the endoglycosidase. Those of skill in the art will recognize the numerous amino acids that can be modified or substituted with other chemically similar residues without substantially altering activity.

As used herein, “modulates” refers to an increase or decrease in “biological activity”, as defined above, when comparing to a glycosylation-engineered antibody of the present invention to a non-glycosylation-engineered antibody.

As used herein, “immunoglobulin molecule” or “antibodies,” refers to molecules that contain an antigen binding site which specifically binds an antigen or an Fc region that binds to cell receptors. Structurally, the simplest naturally occurring antibody (e.g., IgG) comprises four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. The natural immunoglobulins represent a large family of molecules that include several types of molecules, such as IgD, IgG, IgA, IgM and IgE. The term also encompasses hybrid antibodies, or altered antibodies, and fragments thereof, including but not limited to Fab fragment(s) and Fc fragment(s).

Antibodies can be fragmented using conventional techniques as described herein and the fragments screened for utility in the same manner as described for whole antibodies. A Fab fragment of an immunoglobulin molecule is a multimeric protein consisting of the portion of an immunoglobulin molecule containing the immunologically active portions of an immunoglobulin heavy chain and an immunoglobulin light chain covalently coupled together and capable of specifically combining with an antigen. Fab and Fc fragments can be prepared by proteolytic digestion of substantially intact immunoglobulin molecules with papain using methods that are well known in the art. However, a Fab or Fc fragment may also be prepared by expressing in a suitable host cell the desired portions of immunoglobulin heavy chain and immunoglobulin light chain using methods known in the art.

As used herein, with respect to antibodies, “substantially pure” means separated from those contaminants that accompany it in its natural state or those contaminants generated or used in the process of the obtaining the antibody. This term further includes the desired product having a single glycosylation state, whether or not this state includes glycosylation at a single site or multiple sites. Typically, the antibody is substantially pure when it constitutes at least 60%, by weight, of the antibody in the preparation. For example, the antibody in the preparation is at least about 75%, in certain embodiments at least about 80%, in certain embodiments at about 85%, in certain embodiments at least about 90%, in certain embodiments at least about 95%, and most preferably at least about 99%, by weight, of the desired antibody. A substantially pure antibody includes a naturally, recombinantly, or synthetically produced antibody.

As used herein, “therapeutically effective amount” refers to an amount that results in an improvement or remediation of the symptoms of the disease or condition.

Antigens useful for attachment as a tag to a modified fucosylated glycoprotein of the present invention and more preferably an antibody or fragment thereof may be a foreign antigen, an endogenous antigen, fragments thereof, or variants having the same functional activity.

As used herein, “endogenous antigen” refers to a protein or part thereof that is naturally present in the recipient animal cell or tissue, such as a cellular protein, an immunoregulatory agent, or a therapeutic agent.

As used herein, “foreign antigen” refers to a protein or fragment thereof, which is foreign to the recipient animal cell or tissue including, but not limited to, a viral protein, a parasite protein, an immunoregulatory agent, or a therapeutic agent.

The foreign antigen may be a protein, an antigenic fragment or antigenic fragments thereof that originate from viral and parasitic pathogens.

Alternatively, the foreign antigen may be encoded by a synthetic gene and may be constructed using conventional recombinant DNA methods; the synthetic gene may express antigens or parts thereof that originate from viral and parasitic pathogens. These pathogens can be infectious in humans, domestic animals or wild animal hosts.

The foreign antigen can be any molecule that is expressed by any viral or parasitic pathogen prior to or during entry into, colonization of, or replication in their animal host.

The viral pathogens, from which the viral antigens are derived include, but are not limited to, Orthomyxoviruses, such as influenza virus (Taxonomy ID: 59771); Retroviruses, such as RSV, HTLV-1 (Taxonomy ID: 39015) and HTLV-II (Taxonomy ID: 11909); Herpes viruses, such as EBV (Taxonomy ID: 10295), CMV (Taxonomy ID: 10358) or herpes simplex virus (ATCC #: VR-1487); Lentiviruses, such as HIV-1 (Taxonomy ID: 12721) and HIV-2 Taxonomy ID: 11709); Rhabdoviruses, such as rabies; Picornoviruses, such as Poliovirus (Taxonomy ID: 12080); Poxviruses, such as vaccinia Taxonomy ID: 10245); Rotavirus Taxonomy ID: 10912); and Parvoviruses, such as adeno-associated virus 1 (Taxonomy ID: 85106).

Examples of viral antigens include, but are not limited to, the human immunodeficiency virus antigens Nef (National Institute of Allergy and Infectious Disease HIV Repository Cat. #183; GenBank accession #AF238278), Gag, Env (National Institute of Allergy and Infectious Disease HIV Repository Cat. #2433; GenBank accession #U39362), Tat (National Institute of Allergy and Infectious Disease HIV Repository Cat. #827; GenBank accession #M13137), Rev (National Institute of Allergy and Infectious Disease HIV Repository Cat. #2088; GenBank accession #L14572), Pol (National Institute of Allergy and Infectious Disease HIV Repository Cat. #238; GenBank accession #AJ237568) and T cell and B cell epitopes of gp120; the hepatitis B surface antigen (GenBank accession #AF043578); rotavirus antigens, such as VP4 (GenBank accession #AJ293721) and VP7 (GenBank accession #AY003871); influenza virus antigens, such as hemagglutinin (GenBank accession #AJ404627); nucleoprotein (GenBank accession #AJ289872); and herpes simplex virus antigens, such as thymidine kinase (GenBank accession #AB047378).

The bacterial pathogens, from which the bacterial antigens are derived, include but are not limited to, Mycobacterium spp., Helicobacter pylori, Salmonella spp., Shigella spp., E. coli, Rickettsia spp., Listeria spp., Legionella pneumoniae, Pseudomonas spp., Vibrio spp., and Borellia burgdorferi.

Examples of protective antigens of bacterial pathogens include the somatic antigens of enterotoxigenic E. coli, such as the CFA/I fimbrial antigen and the nontoxic B-subunit of the heat-labile toxin; pertactin of Bordetella pertussis, adenylate cyclase-hemolysin of B. pertussis, fragment C of tetanus toxin of Clostridium tetani, OspA of Borellia burgdorferi, protective paracrystalline-surface-layer proteins of Rickettsia prowazekii and Rickettsia typhi, the listeriolysin (also known as “Llo” and “Hly”) and/or the superoxide dismutase (also know as “SOD” and “p60”) of Listeria monocytogenes; the urease of Helicobacter pylori, and the receptor-binding domain of lethal toxin and/or the protective antigen of Bacillus anthrax.

Example of antigens from biological weapons or pathogens include, but are not limited to, smallpox, anthrax, tularemia, plague, listeria, brucellosis, hepatitis, vaccinia, mycobacteria, coxsackievirus, tuberculosis, malaria, erhlichosis and bacterial meningitis.

The parasitic pathogens, from which the parasitic antigens are derived, include but are not limited to, Plasmodium spp., such as Plasmodium falciparum (ATCC#: 30145); Trypanosome spp., such as Trypanosoma cruzi (ATCC#: 50797); Giardia spp., such as Giardia intestinalis (ATCC#: 30888D); Boophilus spp.; Babesia spp., such as Babesia microti (ATCC#: 30221); Entamoeba spp., such as Entamoeba histolytica (ATCC#: 30015); Eimeria spp., such as Eimeria maxima (ATCC#40357); Leishmania spp., (Taxonomy ID: 38568); Schistosome spp., such as Schistosoma mansoni (GenBank accession #AZ301495); Brugia spp., such as Brugia malayi (GenBank accession #BE352806); Fascida spp., such as Fasciola hepatica (GenBank accession #AF286903); Dirofilaria spp., such as Dirofilaria immitis (GenBank accession #AF008300); Wuchereria spp., such as Wuchereria bancrofti (GenBank accession #AF250996); and Onchocerca spp; such as Onchocerca volvulus (GenBank accession #BE588251).

Examples of parasite antigens include, but are not limited to, the pre-erythrocytic stage antigens of Plasmodium spp. such as the circumsporozoite antigen of P. falciparum (GenBank accession #M22982) P vivax (GenBank accession #M20670); the liver stage antigens of Plasmodium spp, such as the liver stage antigen 1 (as referred to as LSA-1; GenBank accession #AF086802); the merozoite stage antigens of Plasmodium spp; such as the merozoite surface antigen-1 (also referred to as MSA-1 or MSP-1; GenBank accession #AF199410); the surface antigens of Entamoeba histolytica, such as the galactose specific lectin (GenBank accession #M59850) or the serine rich Entamoeba histolytica protein; the surface proteins of Leishmania spp, such as 63 kDa glycoprotein (gp63) of Leishmania major (GenBank accession #Y00647 or the 46 kDa glycoprotein (gp46) of Leishmania major; paramyosin of Brugia malayi (GenBank accession #U77590; the triose-phosphate isomerase of Schistosoma mansoni (GenBank accession #WO6781; the secreted globin-like protein of Trichostrongylus colubriformis (GenBank accession #M63263; the glutathione-S-transferases of Fasciola hepatica (GenBank accession #M77682; Schistosoma bovis (GenBank accession #M77682); S. japonicum (GenBank accession #U58012; and KLH of Schistosoma bovis and S. japonicum (Bashir, et al., supra).

Examples of tumor specific antigens include prostate specific antigen (PSA), TAG-72 and CEA; human tyrosinase (GenBank accession #M27160); tyrosinase-related protein (also referred to as TRP; GenBank accession #AJ132933); and tumor-specific peptide antigens.

Examples of transplant antigens include the CD3 molecule on T cells and histocompatibility antigens such as HLA A, HLA B, HLA C, HLA DR and HLA.

Examples of autoimmune antigens include IAS β chain, which is useful in therapeutic vaccines against autoimmune encephalomyelitis (GenBank accession #D88762); glatamic acid decarboxylase, which is useful in therapeutic vaccines against insulin-dependent type 1 diabetes (GenBank accession #NM013445); thyrotropin receptor (TSHr), which is useful in therapeutic vaccines against Grave's disease (GenBank accession #NM000369) and tyrosinase-related protein 1, which is useful in therapeutic vaccines against vitiligo (GenBank accession #NM000550).

HIV drugs that may be used in the construction of the tagged antibodies or fragments thereof include, but are not limited to antiviral agents such as nucleoside RT inhibitors, CCR5 inhibitors/antagonists, viral entry inhibitors and their functional analogs. Specifically, an antiviral agent may nucleoside RT inhibitors, such as Zidovudine (ZDV, AZT), Lamivudine (3TC), Stavudine (d4T), Didanosine (ddI), Zalcitabine (ddC), Abacavir (ABC), Emirivine (FTC), Tenofovir (TDF), Delaviradine (DLV), Efavirenz (EFV), Nevirapine (NVP), Saquinavir (SQV), Ritonavir (RTV), Indinavir (IDV), Nelfinavir (NFV), Amprenavir (APV), Lopinavir (LPV), Atazanavir, Combivir (ZDV/3TC), Kaletra (RTV/LPV), Trizivir (ZDV/3TC/ABC);

CCR5 inhibitors/antagonists, such as SCH-C, SCH-D, PRO 140, TAK 779, TAK-220, RANTES analogs, AK602, UK-427, 857, monoclonal antibodies; and viral entry inhibitors, such as Fuzeon (T-20) (enfuvirtide), NB-2, NB-64, T-649, T-1249, SCH-C, SCH-D, PRO 140, TAK 779, TAK-220, RANTES analogs, AK602, UK-427, 857; and functional analogs or equivalents thereof.

It is envisioned that many different fucosylated polypeptide and fucosylated glycoproteins can be modified according to the methods of the present invention or used as a therapeutic agent for conjugation to a terminal sugar including but not limited to, adrenocorticotropic hormone (ACTH); adrenocorticotropic hormone derivatives (e.g., ebiratide); angiotensin; angiotensin II; asparaginase; atrial natriuretic peptides; atrial sodium diuretic peptides; bacitracin; beta-endorphins; blood coagulation factors VII, VIII and IX; blood thymic factor (FTS); blood thymic factor derivatives; bombesin; bone morphogenic factor (BMP); bone morphogenic protein; bradykinin; caerulein; calcitonin gene related polypeptide (CGRP); calcitonins; CCK-8; cell growth factors (e.g., EGF; TGF-alpha; TGF-beta; PDGF; acidic FGF; basic FGF); cerulein; chemokines; cholecystokinin; cholecystokinin-8; cholecystokinin-pancreozymin (CCK-PZ); colistin; colony-stimulating factors (e.g. CSF; GCSF; GMCSF; MCSF); corticotropin-releasing factor (CRF); cytokines; desmopressin; dinorphin; dipeptide; dismutase; dynorphin; eledoisin; endorphins; endothelin; endothelin-antagonistic peptides; endotherins; enkephalins; enkephalin derivatives; epidermal growth factor (EGF); erythropoietin (EPO); follicle-stimulating hormone (FSH); gallanin; gastric inhibitory polypeptide; gastrin-releasing polypeptide (GRP); gastrins; G-CSF; glucagon; glutathione peroxidase; glutathio-peroxidase; gonadotropins (e.g., human chorionic gonadotrophin and .alpha. and .beta. subunits thereof); gramicidin; gramicidines; growth factor (EGF); growth hormone-releasing factor (GRF); growth hormones; hormone releasing hormone (LHRH); human artrial natriuretic polypeptide (h-ANP); human placental lactogen; insulin; insulin-like growth factors (IGF-I; IGF-II); interferon; interferons (e.g., alpha- beta- and gamma-interferons); interleukins (e.g. 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11 and 12); intestinal polypeptide (VIP); kallikrein; kyotorphin; luliberin; luteinizing hormone (LH); luteinizing hormone-releasing hormone (LH-RH); lysozyme chloride; melanocyte-stimulating hormone (MSH); melanophore stimulating hormone; mellitin; motilin; muramyl; muramyldipeptide; nerve growth factor (NGF); nerve nutrition factors (e.g. NT-3; NT-4; CNTF; GDNF; BDNF); neuropeptide Y; neurotensin; oxytocin; pancreastatin; pancreatic polypeptide; pancreozymin; parathyroid hormone (PTH); pentagastrin; polypeptide YY; pituitary adenyl cyclase-activating polypeptides (PACAPs); platelet-derived growth factor; polymixin B; prolactin; protein synthesis stimulating polypeptide; PTH-related protein; relaxin; renin; secretin; serum thymic factor; somatomedins; somatostatins derivatives; superoxide dismutase; taftsin; tetragastrin; thrombopoietin (TPO); thymic humoral factor (THF); thymopoietin; thymosin; thymostimulin; thyroid hormone releasing hormone; thyroid-stimulating hormone (TSH); thyrotropin releasing hormone TRH); trypsin; tuftsin; tumor growth factor (TGF-alpha); tumor necrosis factor (TNF); tyrocidin; urogastrone; urokinase; vasoactive intestinal polypeptide; and vasopressin.

Fucosylated glycoproteins are an important class of biomolecules that play crucial roles in many biological events such as cell adhesion, tumor metastasis, pathogen infection, and immune response. As indicated previously herein, a major problem in structural and functional studies of fucosylated glycoproteins is their structural microheterogeneity. Natural and recombinant fucosylated glycoproteins are typically produced as a mixture of glycoforms that differ only in the structure of the pendent oligosaccharides.

Referring now, more specifically, to the invention and various aspects and embodiments thereof, the present invention provides a chemoenzymatic method for the preparation of homogeneous fucosylated glycoproteins, including both natural and tailor-made fucosylated glycoproteins. The present invention is based on the fact that synthetic sugar oxazolines can serve as efficient donor substrates of some endoglycosidases (ENGases) for transferring to a fucosylated-GlcNAc-peptide and fucosylated-GlcNAc-protein acceptor to form a new fucosylated glycopeptide and fucosylated glycoprotein in a stereo- and regio-specific manner, and in a high-yield.

Generally, the method includes two key steps: a) the preparation of the acceptor, a fucosylated GlcNAc-protein or a fucosylated GlcNAc-peptide and b) endoglycosidase (ENGase)-catalyzed transfer of an oligosaccharide moiety from a pre-assembled donor substrate, including but not limited to a synthetic oligosaccharide oxazoline or other activated donors including a modified oxazoline to the fucosylated GlcNAc-protein or fucosylated GlcNAc-peptide to form the desired fucosylated glycoprotein or fucosylated glycopeptides.

Thus, the invention provides a general method for glycoprotein remodeling comprising the treatment of the natural or recombinant fucosylated glycoproteins with an endo-enzyme (Endo-A, Endo-H, Endo-M, etc., depending on the nature of the N-glycans to be removed and the substrate specificity of the respective endo-enzymes), which will hydrolyze the bond between the two GlcNAc residues in the N-acetylchitobiose core of the N-glycans to afford the GlcNAc-protein, with the inner GlcNAc residue being still attached to the original glycosylation sites, as shown in the simplified illustration of FIG. 17. Notably, the fucosylated core is shown wherein the fucose moiety is attached to a GlcNAc moiety positioned adjacent to the protein moiety. Then a prepared N-glycan with the desired sugar component (defined monosaccharide residues and linkage types) will be attached to the original glycosylation site(s) by the high-yield enzymatic oligosaccharide transfer from synthetic sugar oxazolines or other activated donor substrates (glycosyl fluoride and aryl glycoside may be used) by an ENGase selected from Endo-F1, Endo-F2, Endo-F3, Endo-D or active mutants thereof. The steps can be easily understood as set forth in FIG. 17.

In this method, the fucosylated GlcNAc-protein or fucosylated GlcNAc-peptide can be prepared by a process such as chemical total protein synthesis, native chemical ligation, expressed protein ligation, etc. A multiplicity of N-glycans can be attached to the fucosylated GlcNAc-protein or fucosylated GlcNAc-peptide in such method

A further aspect of the invention relates to a method of remodeling an antibody including a heterogeneous sugar chain, including:

-   -   (a) removing the heterogeneous sugar chain from the antibody         with an endoglycosidase to leave a single fucosylated GlcNAc         moiety attached to an original glycosylation site; and     -   (b) transferring a core oligosaccharide to said fucosylated         GlcNAc moiety by ENGase-catalyzed transglycosylation to yield a         remodeled antibody.

FIGS. 16, 18 and 19 provide simplified schemes for remodeling of a full antibody have both Fab and Fc regions available or just the Fc region.

Such method may further include incorporating a functional component into the tagged antibody by selective ligation reaction to yield a functionalized antibody. The antibody may for example be functionalized for drug delivery, targeting a specific antigen, etc. The antibody may be functionalized with a functional component selected from among antigens, toxins, radioactive species, photoactive species, and polyethylene glycols. In a specific embodiment, the functionalized antibody is functionalized with alpha-Gal. The antibody itself may be of any suitable type, and may for example be an immunoglobulin, an antibody fragment, or other antibody species.

The endoglycosidase employed in such method is selected from Endo-F1, Endo-F2, Endo-F3, Endo-D and mutants thereof. The remodeled glycoproteins or glycopeptides, such as antibodies can be subjected to any further structural modifications that are necessary or desired, including, without limitation, glycosyl transfer, and selective ligation (e.g., click chemistry, Staudinger reaction, etc.) to introduce the additional functional groups or tags. The functional groups can be of any suitable type, including, without limitation, toxins, special antigens (such as alpha-Gal), radioactive species, photoactive species, PEGs, etc. The glycoprotein can be catalytically reacted in a “click chemistry” cycloaddition reaction of the azide functionality of the glycoprotein with an alkyne bearing the functional moiety of interest. The azido and alkyne functional groups can be switched in the respective ligation components, and the glycoprotein can be functionalized with an alkynyl functionality and reacted with an azide-functionalized compound including the moiety of interest. It will also be appreciated that other ligation pairs can be devised for the click chemistry reaction.

The present invention provides a novel transglycosylation activity of Flavobacterium meningosepticum endoglycosidases, that being Endo-F1, Endo-F2 and Endo-F3, that enables transfer of oligosaccharide en bloc to fucosylated GlcNAc-peptide acceptor to form core-fucosylated glycopeptides. The transglycosylation activity of Endo-F1, Endo-F2 and Endo-F3 is specific for fucosylated GlcNAc acceptor, as transglycosylation activity on non-fucosylated GlcNAc acceptor are not detected under the same reaction conditions. The invention provides a highly convergent method for the synthesis and glycosylation remodeling of a class of biomedically important glycopeptides and glycoproteins such as recombinant monoclonal antibodies.

The present invention opens a new avenue for the synthesis of core fucosylated glycopeptides that are heretofore have been difficult to obtain by isolation from natural sources (because of structural heterogeneity in protein glycosylation) or by conventional chemical synthesis. The novel transglycosylation activity of Endo-F1, Endo-F2 and Endo-F3 now permits a highly convergent method for the synthesis of these compounds.

The present invention can be used to generate various core-fucosylated glycopeptides as biomarkers for cancer diagnosis. It is reported that tumor progression accompanies significant increase in core fucosylation of some glycoproteins.

The present invention can also be used to perform direct glycosylation remodeling of human IgG1-Fc and recombinant monoclonal antibodies. Natural and recombinant human IgG antibodies usually carry core fucose. A combined use of Endo-S (for de-glycosylation of fucosylated glycan) and Endo-F3 (or Endo-F2, Endo-D or their mutants) (for specifically adding back desired glycan) enables the glycosylation remodeling: of this class of glycoproteins. It should be emphasized that commonly used endoglycosidases such; as Endo-A and Endo-M cannot work on a fucosylated GlcNAc-protein acceptor. This invention addresses specifically this limitation.

The fucosylated glycopeptides and glycoproteins, produced according to the methods described herein, can be used for diagnosis and therapeutics. Approximately two-thirds of therapeutic proteins used on the market and/or currently in clinical trials are glycoproteins. However, the structural heterogeneity in different glycoforms of natural and recombinant glycoproteins presents a major barrier in developing glycoprotein-based drugs, as different glycoforms may have different biological activities and controlling glycosylation to a homogeneous glycoform is extremely difficult during expression. The previous discovery of the transglycosylation activity of a class of endoglycosidases represents a major advance in the field for glycosylation engineering to enhance glycoproteins' therapeutic and diagnostic potentials. However, the currently used endoglycosidases such as Endo-A and Endo-M are unable to work on core-fucosylated natural and recombinant glycoproteins. Thus, the discovery of the new property of Endo-F2, Endo-F3, Endo-D and their glycosynthase mutants.

The features and advantages of the present invention are more fully shown by the following non-limiting examples.

EXAMPLES Chemical Synthesis of Asn-Linked Disaccharide Derivative Fmoc-Asn(Fucα1,6GlcNAc)-OH

For screening the transglycosylation activity of ENGases on fucosylated GlcNAc acceptor, an Asn-linked disaccharide derivative was synthesized, that being, Fmoc-Asn(Fucα1,6GlcNAc)-OH (9), using the peracetylated GlcNAc-azide (1) [57] as the starting material, wherein the steps are shown in FIG. 1. Selective α-1,6-fucosylation [58] of 3 with per-O-trimethylsilyl α-fucopyranosyl iodide (4) as the glycosyl donor in the presence of 2,6-di-tert-butylpyridine, followed by in situ removal of the TMS protecting groups, gave the disaccharide derivative 5 in 61% yield. The newly formed glycosidic linkage was confirmed to be α-linkage as demonstrated by a relatively small coupling constant between H-1 and H-2 of the fucose (H-1, δ 4.82, d, J_(1.2)=3.68 Hz). After changing the O-protecting groups to O-acetyl groups, the resulting glycosyl azide 6 was reduced with Me₃P in THF and then coupled with Fmoc-Asp-OtBu to afford the Asn-linked derivative 7. The tert-butyl group was selectively removed with a mild acid condition (20% TFA in CH₂Cl₂) without cleavage of the acid-labile α-1,6-fucosidic linkage to give the Asn-linked disaccharide 8 in 95% yield. Finally selective de-O-acetylation of 8 was achieved by treatment of 8 with K₂CO₃ in MeOH/THF to provide the N-Fmoc-protected Asn-disaccharide (9) in 85% yield, as shown in FIG. 1.

Screening of Transglycosylation Activity Using the Fucosylated GlcNAc-Asn as the Acceptor Substrate and Synthetic Sugar Oxazolines as the Donor Substrates

With the synthetic disaccharide acceptor (9) in hand, a series of ENGases were screened for their ability to transfer an oligosaccharide to the Fucα1,6GlcNAc moiety. These include Endo-A ^([59]) and Endo-M [60], Endo-H from Streptomyces plicatus [73], Endo-D from Streptococcus pneumoniae [63]; and Endo-F1, Endo-F2, and Endo-F3 from Flavobacterium meningosepticum [74-77]. These enzymes all hydrolyze N-glycans at the N,N′-diacetylchitobiose core, but they have different substrate specificity. It is known that Endo-A, Endo-H, and Endo-F1 hydrolyze high-mannose type and/or hybrid type N-glycans [59, 74, 73]; Endo-M can hydrolyze high-mannose type, hybrid type, and non-fucosylated bi-antennary complex-type N-glycans [60]; Endo-D is specific for a truncated and core-fucosylated N-glycan [63]; and Endo-F2 and Endo-F3 are able to cleave both core-fucosylated and non-fucosylated complex-type N-glycans [75, 76, 77], but Endo-F3 prefers core-fucosylated N-glycans [78]. Two synthetic sugar oxazolines, the Man3GlcNAc-oxazoline (10) [42] and the sialylated N-glycan oxazoline (12) [56], were used as donor substrates for screening the enzymes. If there was a transglycosylation activity, a corresponding core-fucosylated glycopeptide (11 or 13) would be produced, as shown in FIG. 2. Thus, a mixture of oxazoline (10) or (12) and acceptor 9 (donor/acceptor, 4:1) was incubated with an appropriate amount of the respective ENGase at 30° C. in a phosphate buffer (50 mM, pH 7.0) containing 10% DMSO. Inclusion of 10% DMSO significantly enhanced the solubility of the Fmoc derivative 9 in the buffer. The course of transglycosylation reaction was monitored by RP-HPLC analysis of reaction aliquots taken at intervals, and new peaks (products) were subject to ESI-MS analysis to confirm their identity. The screening results were summarized in FIG. 3. It was revealed that Endo-A, Endo-M, wild type Endo-D, and Endo-H did not show any transglycosylation activity towards the α-1,6-fucosylated GlcNAc derivative, although the first three enzymes were previously shown to be able to transglycosylate non-fucosylated GlcNAc-Asn acceptor. In contrast, the Endo-F3 demonstrated remarkable transglycosylation activity toward the α-1,6-fucosylated GlcNAc acceptor, with both the truncated glycan oxazoline (10) and the full-size complex type glycan oxazoline (12). The reaction led to the formation of the corresponding core-fucosylated N-glycan (11) and (13) respectively, in over 70% yield within 1 h. The yield was based on the conversion of the acceptor. It should be mentioned that only a single transglycosylation product was formed when oxazoline 10 or 12 were used, indicating the specificity for the enzymatic transglycosylation. A HPLC profile of the reaction between oxazoline 10 and acceptor 9 in the presence of Endo-F3 was shown in FIG. 4. It was found that a gradual hydrolysis of the product by Endo-F3 occurred when the mixture was incubated with the enzyme for a prolonged time. This was expected, due to the inherent hydrolytic activity of Endo-F3. However, the Endo-F3 catalyzed transglycosylation from the sugar oxazoline was surprisingly fast, allowing a significant accumulation of the transglycosylation product. These results suggest that the use of the highly active sugar oxazoline as donor substrate favours the transglycosylation. The Endo-F2 also showed transglycosylation activity on the 1,6-fucosylated GlcNAc acceptor, but the reaction was much slower than that catalyzed by Endo-F3. In comparison, the Endo-F1 only showed marginal transglycosylation activity when Man3GlcNAc-oxazoline (10) was used as donor substrate, and did not show any activity when the sialylated glycan oxazoline (12) was used as donor substrate (FIG. 3). These results clearly demonstrate the distinct substrate specificity of these endoglycosidases in transglycosylation. Products 11 and 13 from the transglycosylation by Endo-F2 and Endo-F3 were purified by RP-HPLC and first characterized by mass spectrometric analysis. The MALDI-TOF MS data of 11 (calculated, M=1392.50; found (m/z), 1416.12 [M+Na]⁺) indicated that the product was an adduct of the Man3GlcNAc-oxazoline and acceptor 9; the ESI-MS of 11 revealed two major m/z species at 1393.58 and 1247.60, which corresponded to [M+H]⁺and [M−Fuc+H]⁺, respectively. The presence of fragment [M−Fuc+H]⁺ suggested that the transferred oligosaccharide was attached to the GlcNAc moiety rather than the Fuc moiety in the acceptor.

Further characterization of product 11 was carried out by specific enzymatic transformations. Endo-D digestion of the isolated 11 gave tetrasaccharide Man₃GlcNAc that was identical to an authentic sample, and the Fmoc-Asn(Fucα1,6GlcNAc)-OH. Since Endo-D is known to specifically cleave the α-1,4-glycosidic linkage in the N,N′-diacetylchitobiose unit of a core-fucosylated Man₃GlcNAc₂ moiety [63], the observed result indicated that the transferred Man3GlcNAc was attached specifically to the 4-OH of the GlcNAc moiety in acceptor 9 to form the desired α-1,4 glycosidic linkage. The sialylated product (13) was similarly characterized by MS analysis. Notably, this is the first report showing a transglycosylation activity of Endo-F2 and Endo-F3 with a sugar acceptor [61]. The Endo-F2 and Endo-F3 also represent the first endoglycosidases capable of glycosylating core fucosylated GlcNAc acceptor to form a new core-fucosylated N-glycopeptide.

Endo-F2 and Endo-F3 Do not Accept Non-Fucosylated GlcNAc Derivative as Acceptor Substrate for Transglycosylation

The significant transglycosylation activity of Endo-F2 and Endo-F3 on Fmoc-Asn(Fucα1,6GlcNAc)-OH also prompted the examination to determine how these Flavobacterium enzymes act on non-fucosylated GlcNAc acceptor. It has been previously shown that Endo-A and Endo-M are very efficient to transglycosylate non-fucosylated GlcNAc moiety [40]. Accordingly, the transglycosylation of Endo-F1, Endo-F2, Endo-F3, and wild type Endo-D on Fmoc-Asn(GlcNAc)-OH (14) was tested using Man₃GlcNAc oxazoline (10) as the donor substrate and shown in FIG. 5. The results were summarized in FIG. 6. Surprisingly, Endo-F2 and Endo-F3 did not exhibit transglycosylation activity on the non-fucosylated GlcNAc acceptor under the screening conditions. On the other hand, the Endo-F1 enzyme, which did not show activity on the fucosylated GlcNAc acceptor as described above, demonstrated significant transglycosylation activity with the non-fucosylated GlcNAc (14) to lead to a rapid formation of the corresponding product (15). The yield reached 45% within 30 min. However, a prolonged incubation did not result in further increase in yield. HPAEC-PAD analysis of the reaction mixture revealed that the moderate yield was mainly due to the simultaneous hydrolysis of the sugar oxazoline (10), which was completely gone within 30 min. Interestingly, the product Man3GlcNAc2-Asn(Fmoc) (15) was not hydrolyzed even for a prolonged incubation, indicating that the truncated N-glycan product was a poor substrate of Endo-F1. The Endo-D is an interesting case. The results indicated that Endo-D could use Man3GlcNAc-oxazoline (10) as donor substrate and GlcNAc-Asn derivative (14) as acceptor for transglycosylation, albeit at a low yield, as shown in FIG. 6. This result is consistent with a recent report on Endo-D [62]. However, when the α-1,6-fucosylated GlcNAc derivative (9) was used, no transglycosylation product was detected, as shown in FIG. 3. Given the fact that Endo-D could efficiently hydrolyze α-1,6-fucosylated Man3GlcNAc2 core [63], it is conceivable to think that Endo-D should be able to accommodate α1-6-fucosylated GlcNAc derivative (9) as acceptor for transglycosylation. The failure to detect the transglycosylation product might be due to the quick Endo-D catalyzed hydrolysis of the product in situ before it was released from the catalytic site. Indeed, incubation of Endo-D and the purified core-fucosylated Man3GlcNAc2-Asn(Fmoc) (11) obtained from the Endo-F3 transglycosylation resulted in a very quick hydrolysis of 11.

The presence of an α-1,6-linked fucose in the GlcNAc acceptor seems essential for recognition of the acceptor by Endo-F2 and Endo-F3 for an efficient transglycosylation. In contrast, attachment of a core fucose on the GlcNAc moiety completely blocked the accommodation of the acceptor for transglycosylation by Endo-F1, Endo-A, and Endo-M. It should be pointed out that the wild type Endo-F2 and Endo-F3 could still hydrolyze the transglycosylation product thus formed. One way to address this issue is to create glycosynthase mutants that is capable of working on the highly activated sugar oxazolines for transglycosylation but lacks product hydrolysis activity. It has been previously shown that site-directed mutation at a specific Asn residue, the Asn175 in Endo-M and Asn171 in Endo-A, which promotes oxazoline formation during hydrolysis, could lead to glycosynthase mutants useful for synthesis [52, 56, 55]. The crystal structure of Endo-F3 was solved and the two conserved active residues at the catalytic site were identified as Asp126 and Glu128 [79]. In the substrate-assisted mechanism of the family 18 endoglycosidases [80-81], the Glu128 of Endo-F3 serves as a general acid to protonate the glycosidic bond; whereas the Asp126 was assigned a secondary role, assumingly having the same function as the Asn171 of Endo-A to promote the formation of the oxazolinium ion intermediate, and to stabilize it, by interactions with the 2-acetamido group in the GlcNAc moiety [79].

Convergent Chemoenzymatic Synthesis of a Sialylated and Core-Fucosylated Complex-Type Glycoform of CD52 Antigen

The remarkable transglycosylation activity of Endo-F2 and Endo-F3 with α-1,6-fucosylated GlcNAc acceptor, together with their flexibility in accepting different sugar oxazolines as donor substrates, opens a new avenue to a highly convergent chemoenzymatic synthesis of core-fucosylated complex type N-glycans, glycopeptides, and/or glycoproteins. As a test case, a sialylated and core-fucosylated complex-type glycoform of the CD52 glycopeptide antigen was synthesize. CD52 is a GPI-anchored glycopeptide antigen found on human lymphocytes and sperm cells. It is a glycopeptide consisting of only 12 amino acid residues but carrying a large complex-type N-glycan at the Asn-3 residue [64-66]. Several truncated CD52 glycoforms were made previously by chemical methods [67-69]. The CD52 antigen was previously used as a model glycopeptide to test our chemoenzymatic method [82, 55, 70]. However, a full-size complex-type CD52 antigen carrying both terminal sialic acid residues and core fucose moiety had not been made by either chemical or chemoenzymatic method. A convergent chemoenzymatic synthesis of the target CD52 antigen required the preparation of a CD52 polypeptide containing a Fucα1,6GlcNAc moiety at the Asn-3. To avoid a strong acidic condition for retrieving the polypeptide from the solid support in the Fmoc approach, the solid-phase peptide synthesis was performed on an acid-labile O-link TGT-resin, which can be cleaved by mild acid treatment, as shown in FIG. 7. Fmoc-Asn(Ac₅Fucα1-6GlcNAc)-OH (8) was used as a building block to replace the residues at Asn-3 during the synthesis to introduce a Fucα1,6GlcNAc moiety. HATU (0.5 M in DMF) and DIPEA (1.0 M in DMF) (1:1, v/v) were used as the coupling reagent and piperidine (20% in DMF) was used as the deblocking reagent. 4-fold excess of Fmoc-protected building blocks were used for each coupling reaction cycle. The N-terminus amino group was protected with an acetyl group by treatment with Ac₂O/DIPEA. The disaccharide-containing polypeptide was released from the resin (16) by treatment with 20% TFA in CH₂Cl₂ at r.t. for 5 h, with simultaneous removal of the side-chain protecting groups (Trt and t-Bu). The Ac groups on the disaccharide were removed by treatment with 5% aqueous hydrazine at r.t. for 1 h. The crude product was then purified by preparative HPLC to give the Fucα1,6GlcNAc-CD52 (17) in an excellent overall yield (90%), FIG. 7. The product was characterized by ESI-MS (calculated, M=1598.64; found (m/z), 1599.16 [M+H]⁺) and a detailed NMR analysis, with results in FIGS. 8, 9 and 10.

With the Fucα1,6GlcNAc-CD52 (17) in hand, the transglycosylation with Endo-F3 was performed, using sialoglycan oxazoline (12) (FIG. 2) as donor substrate, which was efficiently synthesized from a free N-glycan by a single-step conversion in water [56]. Thus, incubation of 12 and 17 (molar ratio: donor/acceptor, 2:1) with Endo-F3 in a phosphate buffer (pH 7.0) led to the formation of the CD52 glycoform (18) carrying a sialylated and core-fucosylated bi-antennary N-glycan. The reaction was monitored by HPLC. When the formation of 18 reached a plateau, the reaction was stopped and the product was isolated in 55% yield by HPLC. The efficiency of the transglycosylation was quite impressive, given the fact that only two-fold of the donor substrate was used. Using the Endo-F2 to replace Endo-F3 for the transglycosylation gave a 25% yield of 18 after a longer period (6 h) of incubation (data not shown). ESI-MS of 18 gave the expected m/z species (calculated for C₁₃₇H₂₂₁N₂₁O₉₀, M=3600.34; found (m/z), 1201.66 [M+3H]³⁺). Further characterization of the product was carried out by specific enzymatic transformations. Digestion of 18 with peptide-N4-(N-acetyl-β-D-glucosaminyl)asparagine amidase F (PNGase F), which specifically hydrolyzes the β-aspartylglucosylamine bond of N-glycopeptides and N-glycoproteins [83-84], yielded the expected sialoglycan 19 (ESI-MS: calculated for C₉₀H₁₄₈N₆O₆₆, M=2368.84; found (m/z), 1185.82 [M+2H]²⁺) and the expected aspartic acid-containing CD52 peptide (20) (ESI-MS: calculated for C₄₇H₇₄N₁₄O₂₆, M=1250.49; found (m/z), 1251.56 [M+H]⁺, 626.38 [M+2H]²⁺ as shown in FIG. 11. On the other hand, incubation of purified 18 with large amount of Endo-F3 gave Fucα1,6GlcNAc-CD52 (17) and the corresponding N-glycan 21, as shown in FIG. 12. These results suggest that the transferred glycan was attached to the GlcNAc in the peptide through the GlcNAc-α-1,4-GlcNAc linkage. Finally, NMR was conducted and a detailed NMR analysis was conducted as shown in FIGS. 14 and 15. A ¹H-¹³C 2D HSQC NMR analysis of 18 permitted the assignment of all the sugar anomeric protons and anomeric carbons, as well as all the amino acid residues in the product, as shown in FIG. 13. These experiment data confirmed that the product obtained was the expected full-size, sialylated and core-fucosylated CD52 antigen.

It has been shown herein that the GH family 18 Flavobacterium meningosepticum endoglycosidases Endo-F2 and Endo-F3 demonstrate novel transglycosylation activities and are able to glycosylated α-1,6-fucosylated GlcNAc-peptide by using sugar oxazoline as a donor substrate. The novel activity of Endo-F2 and Endo-F3 was successfully applied for a convergent chemoenzymatic synthesis of a full-size CD52 glycopeptide antigen carrying both terminal sialic acid and core fucose. This is the first discovery of transglycosylation activity of Endo-F1, Endo-F2 and Endo-F3 that show distinct acceptor substrate specificity. This is the first report on endoglycosidases capable of taking core-fucosylated GlcNAc-peptides for transglycosylation. In addition to the usefulness for complex glycopeptide synthesis, the unusual transglycosylation activity discovered may be used for glycosylation remodelling of monoclonal antibodies that usually carry core fucosylated N-glycans at the Fc domain but can be specifically de-glycosylated by an endoenzyme to provide a core-fucosylated GlcNAc acceptor at the glycosylation site.

Cloning and Expression of Wild Type Endo-F3 and the D126A (SEQ ID NO: 6) and D126Q (SEQ ID NO: 7) Mutants.

Standard molecular cloning and site-directed mutagenesis methods were used. Initial cloning of the Endo-F3 gene into the PGEX-2T vector and its transformation in E. coli for expression resulted in formation of inclusion bodies after overexpression in E. coli. The inclusion bodies were solubilized in 8M urea and refolded with about 6% efficiency resulting in an active fusion protein. This procedure gave an active Endo-F3 enzyme but the overall expression efficiency was low. Alternatively, the Endo-F3 gene was cloned into the pCPD4 vector which has been shown to help protein solubility. The resulting plasmid pCPD-EndoF3 was used for transforming E. coli (BL21 DE3) and led to a high-yield (35-50 mg/liter) expression of soluble fusion protein EndoF3-PCD, which showed high activity for N-glycan hydrolysis and also for transglycosylation.

For the expression of the D126A and D126Q mutants, the QuickChange site-directed mutagenesis kit (Stratagene) was applied to generate the mutants. Briefly, primers containing the desired mutation were used to perform PCR using pCPD-EndoF3 as a template. After PCR the template DNA was digested with DpnI and then the mixture was transformed into DH5α max efficiency cells (Invitrogen). The resulting plasmid was isolated and used to transform E. coli (BL21 DE3) to over produce the respective mutants. Related Endo-F1 and Endo-F 2 mutants were overproduced in a similar manner.

EndoF3 Mutants Catalyzed Transglycosylation Using Complex-Type Sialoglycan Oxazoline (12) as Donor Substrate and Fmoc-Asn(Fucα1,6GlcNAc)-OH (9) as Acceptor Substrate.

A mixture of acceptor 9 (25 μg, 36 nmol) and sialoglycan oxazoline 12 (290 μg, 145 nmol) in phosphate buffer (50 mM, pH 7.0, 12 μL) was incubated at 30° C. with Endo F3 D126A (SEQ ID NO: 6) (12 μg) or Endo F3 D126Q (SEQ ID NO: 7) (6 ug) for 18 h. The reaction was monitored by analytic HPLC. The product was purified by RP-HPLC to give Fmoc-Asn(Sia₂Gal₂GlcNAc₂Man₃GlcNAc₂Fuc)-OH (13) as characterized by HPLC and ESI-MS as described above. FIG. 22 shows the time courses of the transglycosylation of the fucosylated GlcNAc acceptor (9) with sialoglycan oxazoline (12) under the catalysis of glycosynthase mutant, Endo-F3 D126A.

Chemoenzymatic Synthesis of Sialylated and Core-Fucosylated Complex-Type Glycoform of CD52 (18) by Endo F3 Mutants.

A mixture of CD52 peptide 17 (2 mg, 1.25 μmol) and sialoglycan oxazoline 12 (5 mg, 2.5 μmol) in phosphate buffer (50 mM, pH 7.0, 250 μL) was incubated at 30° C. with Endo-F3 D126A (SEQ ID NO: 6) (240 μg) or Endo F3 D126Q (SEQ ID NO: 7) (160 ug) for 18 h. The reaction was quenched with 1% TFA (10 μL) and the residue was subject to preparative RP-HPLC to give CD52-Sia₂Gal₂GlcNAc₂Man₃GlcNAc₂Fuc (18) as a white powder (yield: >90%). The product was characterized by HPLC, ESI-MS, and NMR as described above.

Chemoenzymatic Synthesis of Core-Fucosylated Complex-Type Glycoform of IgG Fc Fragment by Endo-F3 Wild-Type and Mutants. Papain Digestion of Full-Length Antibody Rituximab.

The antibody was digested with protease papain according the reported method [87] with some modifications. Briefly, a solution of rituximab (20 mg) in a Tris-Cl buffer (20 mM, pH 6.5, 20 mL) containing L-cysteine (2 mM) was incubated with papain (200 μg) at 37° C. The reaction was monitored by SDS-PAGE and LC-MS. When the production of an Fc fragment reached plateau (after 2 h), the reaction mixture was loaded on a column of protein A-agarose resin (5 ml) that was pre-equilibrated with a Tris-Cl buffer (20 mM, pH 8.0). The column was washed with Tris-Cl (20 mM, pH 8.0, 25 mL) and glycine-HCl (20 mM, pH 5.0, 20 mL) successively. The bound Fc fragments were then eluted with glycine-HCl (100 mM, pH 2.5, 20 mL) and the elution fractions were immediately neutralized with Tris-Cl buffer (1.0 M, pH 8.8). The fractions containing the Fc fragments were combined and concentrated by centrifugal filtration (Amicon® ultra centrifugal filter, Millipore, Billerica, Mass.) to give IgG-Fc (3.5 mg). LC-MS: calculated for non-glycosylated IgG-Fc dimer, M=49896; found (after deconvolution): 52763 (G0F/G0F homodimer), 52925 (G0F/G1F heterodimer), 53084 (G1F/G1F homodimer), and 53400 (G2F/G2F homodimer).

De-Glycosylation of the Fc Fragments by Endo-S to Prepare Fucα1,6GlcNAc-Fc.

A solution of the purified IgG-Fc (2 mg) in a Tris-Cl buffer (50 mM, pH 7.0, 0.4 mL) was incubated with Endo-S (20 μg) at 30° C. After 30 min, the SDS-PAGE and LC-MS indicated the completion of the deglycosylation. The product was then purified through protein-A affinity chromatography following the procedures described above to give the Fucα1,6GlcNAc-Fc (2 mg, quantitative yield). ESI-MS: calculated for Fucα1,6GlcNAc-Fc, M=50594; found (based on deconvolution of the MS spectrum), M=50573.

Transglycosylation to Fucα1,6GlcNAc-Fc by EndoF3 Wild-Type or Mutants.

A solution of Fucα1,6GlcNAc-Fc (5 mg) and sialoglyan oxazoline 12 (10 mg) in a phosphate buffer (50 mM, pH 7.0, 500 μl) was incubated with the Endo F3 (250 ug) or Endo F3 D126A (500 mg) or Endo F3 D126Q (250 mg) at 30° C. The reactions were monitored by LC-MS. After 5 h, the resulted Sia₂Gal₂GlcNAc₂Man₃GlcNAc₂Fuc-Fc was purified through the protein-A affinity column as described above. ESI-MS: calculated for Sia₂Gal₂GlcNAc₂Man₃GlcNAc(α1,6Fuc)GlcNAc-Fc homodimer, MW=53263 Da; found (based on deconvolution of MS data), 53266.

Chemoenzymatic Synthesis of Core-Fucosylated Complex-Type Glycoform of Full Length IgG by Endo-F3 Wild-Type and Mutants. Cleavage of Native Glycoforms of Rituximab by Wide-Type Endo-S to Give Rituximab-GlcNAcFuc.

Commercial rituximab (20 mg) in a Tris-Cl buffer (50 mM, pH 8.0, 2 mL) was incubated with wide-type Endo-S (30 ug) at 37° C. for 1 h. LC-MS and SDS-PAGE analysis indicated the complete cleavage of the N-glycans on the heavy chain. The residue was subjected to an affinity chromatography column of protein A-agarose resin to give the rituximab-GlcNAcFuc (18 mg). LC-MS: calculated for rituximab-GlcNAcFuc heavy chain, M=49420 (J. Chromatography A, 2001, 913, 437-446); found, 49420 (deconvolution). See FIG. 23.

Endo-F3 WT and Mutants Catalyzed Transglycosylation on Rituximab-GlcNAcFuc Using Sialoglycan Oxazoline 12 as Donor Substrate.

A solution of rituximab-GlcNAcFuc (10 mg) and sialoglycan-oxazoline 12 (10 mg) in a Tris buffer (50 mM, pH 7.4, 1 mL) was incubated with the Endo-F3 (500 ug) or Endo-F3 D126A (1 mg) or Endo-F3 D126Q (500 ug) at 30° C. The reactions were monitored by LC-MS. After 5 h, the reaction mixture was subject to an affinity chromatography on a protein A-agarose column following the procedure described above. Fractions containing the product were combined and concentrated by ultracentrifugation to give rituximab-GlcNAcFuc-SCT. LC-MS: calculated for rituximab-GlcNAcFuc-SCT heavy chain, M=51421; found, 51426 (deconvolution). Schematic showing transglycosylation can be viewed in FIG. 23.

Cloning, Expression and Purification of Endo-D in Escherichia Coli.

The cDNA fragment encoding the Endo-D fragment (nucleotides 403-3141 (SEQ ID NO: 14); amino acid 135-1047 (as shown in SEQ ID NO: 11)), here called Endo-D, was amplified by PCR from the genomic DNA of Streptococcus pneumoniae (ATCC number: BA.A.-334D-5). The forward primer was 5′-TATATACATATGGAGTCTA.A.ACCAGCAGCAGAAGC-3′(SEQ ID NO: 12), and the reverse primer was 5′-GCGCGCCTCGAGTTCTTCTGTCATCTTTTGGAACGG-3′ (SEQ ID NO: 13). NdeI and XhoI site (underlined) were added to the forward and reverse primers, respectively. The cDNA fragment of a further truncated form (nucleotides 475-2471; amino acid 157-807) of Endo-D (called spGH85) was cloned following the previously reported procedure [88]. Both of the amplified DNA fragments were cloned into pET28a (Novagen) after digestion with NdeI and XhoI. The constructed plasmids, pET28a-EndoD and pET28a-spGH85, respectively, were transformed into BL21 (DE3). The transformants were cultured in LB media supplemented with 50 μg/ml kanamycin. Cultures were grown at 37° C. until the cells reached an absorbance of 0.5-0.8 at 600 nm. Then 0.5 mM isopropyl β-D-1-thiogalactopyranoside was added to the culture to induce protein overproduction. After further incubation at 25° C. for 8 h, the cells were harvested by centrifugation. The cell pellets was suspended in a sodium phosphate buffer (50 mM, pH 7.0) with lysozyme before sonication. After sonication and centrifugation, the supernatant from the cell lysis was applied onto Ni²⁺-immobilized HisTrap HP column (GE Healthcare). The column was washed with 50 mM imidazole and then eluted with 200 mM imidazole in a buffer containing 0.5 M NaCl and 0.1 M sodium phosphate (pH 7.4). The eluent was desalted and concentrated by Amicon ultra filtration (10 kDa, Millipore). The homogeneity of the recombinant Endo-D and spGH85 was confirmed by SDS-PAGE with Coomassie Brilliant Blue staining. The protein concentration was quantified using the Bradford assay protocol with bovine serum albumin (BSA) as standards.

Site-Directed Mutagenesis of Endo-D.

The selected mutants (N322A (SEQ ID NO: 8), N322Q (SEQ ID NO: 9), E324Q, Y360F, and H371W all available with changes SEQ ID NO: 11) were generated using the GENEART Site-Directed Mutagenesis Kit (Invitrogen) per the manufacturer's directions, The pET28a-EndoD plasmid encoding the Endo-D gene (nucleotides 403-3141; amino acid 135-1047) was used as the template and LA Taq polymerase (Takara, Japan) was used for PCR. Mutations were confirmed by DNA sequencing and transformed into BL21 (DE3). Expression and purification of mutants were carried out in the same way as for the wild-type enzyme.

Assay for the Transglycosylation Activity of Endo-D and its Mutants.

The transglycosylation activity of the enzyme was assayed as follows: a mixture of Man₃GlcNAc-oxazoline (5 mM) and Fmoc-Asn(Fucα1,6GlcNAc)-OH (0.5 mM) or Fmoc-Asn(GlcNAc)-OH (0.5 mM) in a sodium phosphate buffer (50 mM, pH 7.5, 5 μl) containing 10% DMSO was incubated with spGH85 (0.19 μg), Endo-D (0.01 μg), or its mutant (0.01 μg) respectively at 30° C. DMSO was added to enhance the solubility of the Fmoc-Asn(GlcNAc)-OH substrate in the aqueous buffer. Aliquots were taken at intervals and the enzymatic reaction was analyzed by RP-HPLC as described above. The yield of the transglycosylation product was calculated by integration of the peak areas and normalized with the absorbance as follows: transglycosylation yield (%)=[product area/(product area+residual acceptor area)]×100%.

EndoD-N322Q Mutant-Catalyzed Transglycosylation of Fucα1,6GlcNAc-Fc and Man3GlcNAc Oxazoline.

A solution of Fucα1,6GlcNAc-Fc (506 μg, 10 nmol) and Man₃GlcNAc-oxazoline (138 μg, 200 nmol) in a Tris buffer (50 mM, pH 6.8, 50 μl) was incubated with the N322Q mutant (10 μg) at 30° C. Aliquots were taken at intervals and were analysis by LC-MS. After 5 h, LC-MS indicated the complete reaction of Fucα1,6GlcNAc-Fc to give a new species corresponding to the transglycosylation product (quantitative yield). ESI-MS: calculated for Man₃GlcNAc(α1,6Fuc)GlcNAc-Fc homodimer, M=51951; found (m/z) (deconvoluted data), 51946.

Materials and Methods

The Fmoc-protected amino acids and Fmoc-Ser(tBu)-O-TGT resin were purchased from Novabiochem Corp (San Diego, Calif.). 2-(1-H-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) was purchased from GenScript Corp (Piscataway, N.J.). Diisopropylethylamine (DIPEA) was purchased from Applied Biosystems (Carlsbad, Calif.). Piperidine (20% in DMF) was purchased from American Bioanalytical (Natick, Mass.). N,N-Dimethylformamide sequencing grade was purchased from Fisher Biotech (Pittsburgh, Pa.). Acetonitrile HPLC grade was purchased from Fisher Scientific (Pittsburgh, Pa.). 3,4,6-Tri-O-acetyl-1,3-azido-GlcNAc (1) was synthesized following reference [57]. 2,3,4-Tri-O-acetyl-fucose-1α-iodide (4) was synthesized by reported method [58]. Man₃GlcNAc oxazoline (10) was synthesized as reported [42]. The bi-antennary complex-type sialoglycan oxazoline (12) was prepared following the reported procedure [56]. Fmoc-Asn(GlcNAc)-OH (14) was prepared by reported procedure [71]. Endo F1, Endo F2, and Endo F3 were purchased from CalBioChem (San Diego, Calif.). Endo H was purchased from New England Biolabs (Ipswich, Mass.). Endo D was purchased from United States Biological (Swampscott, Mass.). Endo-A was overproduced in E. coli and purified following the previously reported procedure [72], using the plasmid pGEX-2T/Endo-A that was kindly provided by Prof Kaoru Takegawa. Endo-M was overproduced according to the previously reported method [52]. PNGase F was purchased from New England Biolabs (Ipswich, Mass.). All other reagents were purchased from Sigma/Aldrich and used as received.

High-Performance Liquid Chromatography (HPLC).

Analytical RP-HPLC was performed on a Waters 626 HPLC instrument with a Symmetry300™ C₁₈ column (5.0 μm, 4.6×250 mm) or a XBridge™ BEH130 C₁₈ column (3.5 μm, 4.6×250 mm) at 40° C. The Symmetry300 column was eluted with a linear gradient of 0-90% MeCN containing 0.1% TFA within 30 min at a flow rate of 1 mL/min (Method A). The XBridge column was eluted with a linear gradient of 0-20% MeCN containing 0.1% TFA within 30 min at a flow rate of 0.5 mL/min (Method B). Preparative HPLC was performed on a Waters 600 HPLC instrument with a preparative Symmetry300™ C₁₈ column (7.0 nm, 19×250 mm) or a XBridge™ Prep ShieldRP18 column (5.0 nm, 10×250 mm). These columns were eluted with a suitable gradient of aqueous acetonitrile containing 0.1% TFA at a flow rate of 12 mL/min (for Symmetry300 column) or 4 mL/min (for XBridge column).

Nuclear Magnet Resonance (NMR).

The ¹H NMR spectra were measured on JEOL ECX 400 MHz or Inova 500 MHz or Bruker DRX 500 MHz NMR spectrometers. All chemical shifts were assigned in ppm. The ¹³C NMR was measured at 125 MHz.

Mass Spectrometry (MS).

The ESI-MS Spectra were measured on a Waters Micromass ZQ-4000 single quadruple mass spectrometer. MALDI-TOF MS measurement was performed on an Autoflex II MALDI-TOF mass spectrometer (Bruker Daltonics). The instrument was calibrated by using ProteoMass Peptide MALDI-MS calibration kit (MSCAL2, Sigma/Aldirich). The matrix used for glycans was 2,5-dihydroxybenzoic acid (DHB) and/or alpha-cyano-4-hydroxycinnamic acid (ACHA) (10 mg/mL in 50% acetonitrile containing 0.1% trifluoroacetic acid). The measuring conditions: 337 nm nitrogen laser with 100 μJ output; laser frequency 50.0 Hz; laser power 30-45%; linear mode; positive polarity; detection range 500-5000; pulsed ion extraction: 70 ns; high voltage: on; realtime smooth: high; shots: 500-2000.

2-Acetamido-3,4-di-O-benzoyl-2-deoxy-6-O-trityl-β-D-glucopyranosyl azide (2)

3,4,6-Tri-O-acetyl-1β-azido-GlcNAc (1) (610 mg, 1.64 mmol) was dissolved in anhydrous MeOH (15 mL) and NaOMe (wt. 25% in MeOH) (2.05 mL, 35.8 mmol) was added. The reaction mixture was stirred for 2 hr under argon. Then it was treated with Dowex 50WX8-100 ion-exchange resin H⁺ form and filtered. The filtrate was concentrated to dryness under vacuum to give the crude 1β-azido-GlcNAc.

A mixture of the crude 1β-azido-GlcNAc from above, pyridine (10 mL) and trityl chloride (0.91 g, 3.25 mmol) was stirred at 60° C. overnight. Then it was cooled to rt and benzoyl chloride (0.47 mL, 4.06 mmol) was added. The solution was continued to stir at room temperature (rt) overnight. The residue was diluted with EtOAc and washed with 1N HCl, saturated NaHCO₃, water, and brine. The organic layer was dried over Na₂SO₄ and concentrated. The syrup was subject to a silica gel column chromatography eluted with EtOAc:Hexane=1:2 (v/v) to the product 2 as white foam (810 mg, 70%, three steps). ¹H NMR (400 MHz, CDCl₃) δ 7.91 (dd, J=8.24, 0.92 Hz, 2H), 7.65 (dd, J=8.24, 1.36 Hz, 2H), 7.32-7.49 (m, 11H), 7.08-7.16 (m, 10H), 5.84 (d, J=8.72 Hz, 1H), 5.72 (dd, J=10.08, 9.6 Hz, 1H), 5.53 (dd, J=10.56, 10.52 Hz, 1H), 4.78 (d, J=9.16 Hz, 1H), 4.30 (dd, J=10.52, 9.16 Hz, 1H), 3.89 (m, 1H), 3.38 (dd, J=10.56, 2.28 Hz, 1H), 3.16 (dd, J=10.52, 4.12 Hz, 1H), 1.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ170.62, 167.17, 164.69, 143.52, 133.77, 133.24, 130.06, 129.66, 129.11, 128.65, 128.31, 127.85, 127.02, 88.59, 86.79, 73.29, 68.75, 62.06, 54.67, 23.35.

2-Acetamido-3,4-di-O-benzoyl-2-deoxy(3D-glucopyranosyl azide (3)

A solution of compound 2 (810 mg, 1.16 mmol) in 80% aqueous AcOH (40 mL) was stirred at 60° C. overnight. Then it was concentrated under vacuum. The residue was diluted with EtOAc and washed with water, brine. The organic layer was dried over Na₂SO₄ and concentrated. The resulted syrup was subject to a silica gel column chromatography using EtOAc:Hexane=1:1 (v/v) as the eluent to give the product 3 as white foam (410 mg, 78%). ¹H NMR (400 MHz, CDCl₃) δ 7.89-7.92 (m, 4H), 7.48-7.52 (m, 2H), 7.33-7.37 (m, 4H), 6.02 (d, J=9.16 Hz, 1H), 5.78 (dd, J=10.56, 9.16 Hz, 1H), 5.50 (dd, J=10.08, 9.64 Hz, 1H), 4.97 (d, J=9.16 Hz, 1H), 4.17 (dt, J=10.52, 9.16 Hz, 1H), 3.84-3.89 (m, 2H), 3.73 (dd, J=12.84, 4.6 Hz, 1H), 1.89 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ170.76, 166.80, 166.01, 133.86, 133.80, 129.94, 128.63, 128.54, 88.76, 77.43, 72.55, 69.08, 61.31, 54.61, 23.29.

2-Acetamido-3,4-di-O-benzoyl-2-deoxy-6-O-(α-L-fucopyranosyl)-β-D-glucopyranosyl azide (5)

To a stirring solution of tetra-O-Trimethylsilyl-α-L-fucopyranoside (1.23 g, 2.72 mmol) in anhydrous CH₂Cl₂ (8 mL), iodotrimethylsilane (0.37 mL, 2.72 mmol) was added and the mixture was stirred at rt for 20 min to give the 2,3,4-Tri-O-acetyl-fucose-iodide (4) in situ. Then, a solution of compound 3 (0.62 g, 1.34 mmol) and 2,6-di-tert-butylpyridine (0.6 mL, 2.72 mmol) in anhydrous CH₂Cl₂ (7 mL) was added to the reaction and the mixture was stirred at rt for 5 h. MeOH (5 mL) was added to remove the TMS group and the reaction solution was stirred for additional 20 min. Then it was treated with Dowex 1X2-100 ion-exchange resin Off form and filtered. The filtrate was concentrated under vacuum and the residue was subject to a silica gel column chromatography using CH₂Cl₂:MeOH=15:1 (v/v) as the eluent to give the product 5 as a white solid (0.5 g, 61%). ¹H NMR (400 MHz, CDCl₃) δ 7.86-7.89 (m, 4H), 7.48 (dt, J=7.32, 1.36 Hz, 2H), 7.25-7.34 (m, 4H), 6.30 (d, J=8.72 Hz, 1H), 5.68-5.75 (m, 2H), 4.93 (d, J=9.64 Hz, 1H), 4.82 (d, J=3.68 Hz, 1H), 4.22 (dd, J=10.08, 9.16 Hz, 1H), 4.09 (dd, J=13.28, 6.4 Hz, 1H), 3.94-4.04 (m, 2H), 3.78-3.84 (m, 2H), 3.58 (dd, J=11.48, 3.68 Hz, 1H), 3.46 (broad s, 1H), 3.10 (d, J=10.52 Hz, 1H), 2.90 (broad s, 1H), 1.87 (s, 3H), 1.26 (d, J=6.44 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ170.96, 166.83, 165.86, 133.98, 133.84, 129.92, 128.65, 128.50, 128.46, 98.44, 88.44, 75.10, 72.64, 71.76, 71.51, 69.49, 68.58, 66.45, 65.05, 54.5, 23.24, 16.20.

2-Acetamido-3,4-di-O-acetyl-2-deoxy-6-O-(tri-O-acetyl-α-L-fucopyranosyl)-β-D-glucopyranosyl azide (6)

A solution of compound 5 (0.5 g, 0.83 mmol) and 0.5 M NaOMe in MeOH (50 μL, 50 μmol) in anhydrous MeOH/THF (1/1, v/v, 20 mL) was stirred at rt under argon for 1 hr. The reaction mixture was treated with Dowex 50WX8-100 ion-exchange resin H form and filtered. The filtrate was concentrated to dryness under vacuum. Pyridine (5 mL) and Ac₂O (5 mL) were added to the residue and the mixture was stirred at rt overnight. Then it was diluted with EtOAc and washed with saturated NaHCO₃, water, and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was subject to a silica gel column chromatography using EtOAc as the eluent to give the product 6 as a white solid (0.46 g, 92%). ¹H NMR (400 MHz, CDCl₃) δ 5.72 (d, J=8.68 Hz, 1H), 5.28-5.33 (m, 2H), 5.24 (dd, J=10.52, 9.16 Hz, 1H), 5.03-5.10 (m, 3H), 4.75 (d, J=9.64 Hz, 1H), 4.16 (dt, J=6.88, 6.4 Hz, 1H), 3.86 (dt, J=10.52, 9.2 Hz, 1H), 3.71-3.79 (m, 2H), 3.51 (dd, J=11.48, 5.04 Hz, 1H), 2.14 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.96 (s, 3H), 1.12 (d, J=6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ68.59, 68.04, 68.00, 66.36, 64.64, 54.33, 23.34, 20.82, 20.79, 20.72 (2C), 20.70, 15.96.

N^(ω)-(2-Acetamido-3,4-di-O-acetyl-2-deoxy-6-O-(tri-O-acetyl-α-L-fucopyranosyl)-N^(α)-(9-fluorenylmethyloxycarbonyl)-L-asparagine tert-butyl ester (7)

To a solution of compound 6 (0.46 g, 0.76 mmol) in THF (10 mL) was slowly added 1.0 M trimethylphosphine in toluene (1.15 mL, 1.15 mmol) and the mixture was stirred at rt for 2 h until TLC showed the reaction is complete. The solvent was removed under vacuum and the residue was dissolved in DMF (2 mL). Then, N^(α)-(9-Fluorenylmethyloxycarbonyl)-L-aspatic acid α-tert-butyl ester (350 mg, 0.85 mmol), HATU (0.5 M in DMF, 4.5 mL, 2.25 mmol), and DIPEA (1.0 M in DMF, 3.0 mL, 3.0 mmol) were added and the mixture was stirred at rt overnight under argon protection. The reaction solution was diluted with EtOAc and washed with water and brine. The organic layer was dried over Na₂SO₄ and concentrated to dryness under vacuum. The residue was subject to a silica gel column chromatography using EtOAc as the eluent to give the product 7 as a white solid (570 mg, 77%, two steps). ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J=7.8 Hz, 2H), 7.63 (t, J=7.32 Hz, 2H), 7.36 (t, J=7.8 Hz, 2H), 7.26-7.31 (m, 2H), 7.15 (broad d, J=8.24 Hz, 1H), 6.35 (d, J=9.16 Hz, 1H), 5.93 (d, J=7.76 Hz, 1H), 5.34 (dd, J=11, 3.64 Hz, 1H), 5.26 (d, J=2.72 Hz, 1H), 5.16 (dd, J=10.96, 3.68 Hz, 1H), 4.98-5.06 (m, 4H), 4.96 (dd, J=9.6, 8.24 Hz, 1H), 4.53 (m, 1H), 4.37 (dd, J=10.52, 7.8 z, 1H), 4.32 (dd, J=10.08, 7.36 Hz, 1H), 4.24 (t, J=7.32 Hz, 1H), 4.06 (dt, J=9.6, 8.24 Hz, 1H), 3.68 (m, 1H), 3.52 (dd, J=11.92, 5.04 Hz, 1H), 2.87 (dd, J=16.52, 4.6 Hz, 1H), 2.68 (dd, J=16.48, 3.64 Hz, 1H), 2.12 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.96 (s, 9H), 1.93 (s, 3H), 1.42 (s, 9H), 1.07 (d, J=6.44 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ172.32, 172.11, 171.17, 170.93, 170.71, 170.25, 170.10, 169.32, 156.56, 144.10, 141.31, 127.69, 127.19, 127.14, 125.46, 125.42, 119.98, 96.84, 82.00, 75.25, 73.13, 71.15, 68.30, 68.02, 67.79, 67.25, 65.47, 64.66, 53.44, 50.94, 47.19, 38.69, 38.03, 27.99 (3C), 23.16, 20.89, 20.81, 20.79, 20.72, 20.56, 15.92.

N^(ω)-(2-Acetamido-3,4-di-O-acetyl-2-deoxy-6-O-(tri-O-acetyl-α-L-fucopyranosyl)-N″-(9-fluorenylmethyloxycarbonyl)-L-asparagine (8)

Compound 7 (100 mg, 0.1 mmol) was dissolved in 20% TFA in CH₂Cl₂ (2 mL) and the mixture was stirred at room temperature for 1 h. The residue was co-evaporated with toluene (3 mL) under vacuum and the resulted white solid was washed with Et₂O (5 mL) to give the pure product 8 (90 mg, 95%). ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J=9.2 Hz, 1H, 1-NH of GlcNAc), 7.84 (m, 3H, 2-NHAc of GlcNAc, Ar—H), 7.68 (d, J=7.6 Hz, 2H, Ar—H), 7.45 (d, J=8.8 Hz, 1H, FmocNH), 7.38 (m, 2H, Ar—H), 7.28 (m, 2H, Ar—H), 5.19-5.15 (m, 3H, H1 of GlcNAc, H3 and H4 of Fuc), 5.03 (t, J=9.6 Hz, 1H, H3 of GlcNAc), 4.91-4.80 (m, 3H, H1 and H2 of Fuc, H4 of GlcNAc), 4.34 (dd, J=7.2, 13.2 Hz, □H of Asn), 4.26-4.15 (m, 4H, H5 of Fuc, CH₂ and H9 of Fmoc), 3.86 (q, J=9.6 Hz, 1H, H2 of GlcNAc), 3.66 (m, 2H, H5 and H6a of GlcNAc), 3.45 (m, 1H, H6b of GlcNAc), 2.65-2.49 (m, 2H, □H of Asn), 2.06 (s, 3H, Ac), 1.99 (s, 3H, Ac), 1.93 (s, 3H, Ac), 1.93 (s, 3H, Ac), 1.90 (s, 3H, Ac), 1.86 (s, 3H, Ac), 1.68 (s, 3H, NHAc), 0.98 (d, J=6.8 Hz, 1H, CH₃ of Fuc); ¹³C NMR (100 MHz, CDCl₃) δ173.5, 170.8, 170.6, 170.3, 170.2, 170.1, 169.9, 169.7, 156.3, 144.3, 141.2, 128.1, 127.6, 125.8, 120.6, 96.5, 78.5, 74.2, 74.0, 71.1, 69.2, 67.9, 67.6, 66.4, 66.2, 64.5, 52.5, 50.5, 47.1, 37.4, 23.1, 21.0, 20.9, 20.8, 16.0. ESI-MS: calculated for C₄₃H₅₁N₃O₁₉, M=913.31, found, 914.47 [M+H]⁺.

N^(ω)-(2-Acetamido-6-O-(α-L-fucopyranosyl)-N″-(9-fluorenylmethyloxycarbonyl)-L-asparagine (9)

A mixture of compound 8 (90 mg, 0.1 mmol), K₂CO₃ (87 mg, 0.63 mmol), and MeOH/THF (3/1, 4 mL) was stirred at room temperature. The reaction was carefully monitored by ESI-MS until the acetyl groups were selectively hydrolyzed. Then 1N HCl was added to neutralize the solution to be pH 2-3. The residue was subject to a preparative HPLC for purification. The product 9 was obtained as a white solid (60 mg, 85%). ¹H NMR (400 MHz, DMSO-d₆+1% D₂O) δ 8.20 (broad d, J=9.16 Hz, 1H), 7.85 (d, J=7.8 Hz, 2H), 7.67 (d, J=5.92 Hz, 2H), 7.39 (t, J=7.8 Hz, 2H), 7.30 (t, J=7.32 Hz, 2H), 4.80 (dd, J=9.2, 6.44 Hz, 1H), 4.59 (d, J=3.2 Hz, 1H), 4.31 (dd, J=7.8, 5.52 Hz, 1H), 4.15-4.25 (m, 3H), 3.83 (dd, J=13.28, 6.4 Hz, 1H), 3.44-3.54 (m, 6H), 3.30 (dd, J=9.64, 9.16 Hz, 2H), 3.09 (t, J=9.16 Hz, 1H), 2.57 (dd, J=16.04, 5.04 Hz, 1H), 2.44 (dd, J=16.04, 7.32 Hz, 1H), 1.74 (s, 3H), 1.03 (d, J=6.88 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d₆+1% D₂O) δ173.38, 171.71, 170.33, 156.56, 144.10, 144.05, 141.12, 128.33, 127.75, 125.70, 120.61, 100.03, 78.96, 77.33, 74.29, 71.95, 70.58, 69.91, 68.51, 67.95, 66.46, 66.38, 54.82, 50.5, 46.98, 37.19, 23.03, 16.81. ESI-MS: calculated for C₃₃H₄₁N₃O₁₄, M=703.25, found, 702.31 [M−H]⁻.

Chemoenzymatic Transglycosylation Assay of Various Endoglycosidases Using Man₃GlcNAc Oxazoline (10) as Donor Substrate and Fmoc-Asn(Fucα1,6GlcNAc)-OH (9) as Acceptor Substrate.

A mixture of acceptor 9 (25 μg, 36 nmol) and Man₃GlcNAc oxazoline (100 μg, 145 nmol) in a phosphate buffer (50 mM, pH 7.0, 12 μL) was incubated at 30° C. with individual Endo-β-N-acetylglucosaminidase (4 μg). The reaction was monitored by analytic HPLC by taking reaction aliquots at 10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 20 h. The yields were calculated based on the peak area of product and starting material acceptor. Total 7 ENGases, including Endo-F1, Endo-F2, Endo-F3, Endo-A, Endo-M, Endo-D, and Endo-H, were measured for their transglycosylation activity in this assay. The time-course results are shown in FIG. 3. Panel A. The product was purified by RP-HPLC to give Fmoc-Asn(Man₃GlcNAc₂Fuc)-OH (11). t_(R)=16.8 min (analytical HPLC, method A). MALDI-TOF MS: Calculated for C₅₉H₈₄N₄O₃₄, M=1392.50; found, 1416.12 [M+Na]; ESI-MS: found 1393.58 [M+H]⁺, 1247.60 [M−Fuc+H]⁺, 1085.43 [M−Fuc−Man+H]⁺, 923.45 [M−Fuc−2Man+H]⁺, 761.39 [M−Fuc−3Man+H]⁺.

Endo-D Digestion of Compound 11.

A solution of 11 (10 μg) in a phosphate butter (50 mM, pH 7.0, 20 μL) was incubated with Endo-D (1 μg) at 30° C. for 2 h. The digestion was monitored by RP-HPLC combined with ESI-MS analysis. It clearly showed the compound 11 disappeared and a new peak emerged in the same position of Fmoc-Asn(Fucα1,6GlcNAc)-OH which was confirmed by ESI-MS analysis. This digestion data validated the β1,4-linkage of N,N′-diacetylchitobiose unit in compound 11.

Chemoenzymatic Transglycosylation Assay of Various Endo-Glycosidases Using Complex-Type Sialoglycan Oxazoline (12) as Donor Substrate and Fmoc-Asn(Fucα1,6GlcNAc)-OH (9) as Acceptor Substrate.

A mixture of acceptor 9 (25 μg, 36 nmol) and sialoglycan oxazoline 12 (290 μg, 145 nmol) in phosphate buffer (50 mM, pH 7.0, 12 μL) was incubated at 30° C. with individual Endo-β-N-acetylglucosaminidase (4 μg). The reaction was monitored by analytic HPLC by taking reaction aliquots at 10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 20 h. The yields were calculated based on the peak area of product and starting material acceptor. Total 7 ENGases, including Endo-F1, Endo-F2, Endo-F3, Endo-A, Endo-M, Endo-D, and Endo-H, were measured for their transglycosylation activity in this assay. The time-course results are shown in FIG. 3. Panel B. The product was purified by RP-HPLC to give Fmoc-Asn(Sia₂Gal₂GlcNAc₂Man₃GlcNAc₂Fuc)-OH (13). t_(R)=16.3 min (analytical HPLC, method A). MALDI-TOF MS: Calculated for C₁₀₇H₁₆₁N₇O₆₉, M=2704.95; found, 2728.48 [M+Na]⁺; ESI-MS: found 1353.98 [M+2H]²⁺, 1208.19 [M−Sia+2H]²′.

Endo-F3 Digestion of Compound 13.

A solution of 13 (10 μg) in a phosphate butter (50 mM, pH 7.0, 20 μL) was incubated with Endo-F3 (2 μg) at 30° C. for 20 h. The digestion was monitored by RP-HPLC combined with ESI-MS analysis. It clearly showed the compound 13 disappeared and a new peak emerged in the same position of Fmoc-Asn(Fucα1,6GlcNAc)-OH and was confirmed by the ESI-MS. This digestion data validated the β1,4-linkage of N,N′-diacetylchitobiose unit in compound 13.

Chemoenzymatic Transglycosylation Assay of Various Endo-Glycosidases Using Man₃GlcNAc Oxazoline (10) as Donor Substrate and Fmoc-Asn(GlcNAc)-OH (14) as Acceptor Substrate.

A mixture of acceptor 14 (20 μg, 36 nmol) and Man₃GlcNAc oxazoline (100 μg, 145 nmol) in phosphate buffer (50 mM, pH 7.0, 12 μL) was incubated at 30° C. with individual Endo-β-N-acetylglucosaminidase (4 μg). The reaction was monitored by analytic HPLC by taking reaction aliquots at 10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 20 h. The yields were calculated based on the peak area of product and starting material acceptor. Total 4 ENGases, including Endo-F1, Endo-F2, Endo-F3, and Endo-D, were measured for their transglycosylation activity in this assay. The time-course results are shown in FIG. 6. The product was purified by RP-HPLC to give Fmoc-Asn(Man₃GlcNAc₂)—OH (15). t_(R)=17.0 min (analytical HPLC, method A). MALDI-TOF MS: Calculated for C₅₃H₇₄N₄O₃₀, M=1246.44; found, 1270.25 [M+Na]⁺; ESI-MS: found 1247.68 [M+H]⁺.

Endo-M Digestion of Compound 15.

A solution of 15 (10 μg) in a phosphate butter (50 mM, pH 7.0, 20 μL) was incubated with Endo-M (1 μg) at 30° C. for 2 h. The digestion was monitored by RP-HPLC combined with ESI-MS analysis. It clearly showed the compound 15 disappeared and a new peak emerged in the same position of Fmoc-Asn(GlcNAc)-OH and was confirmed by the ESI-MS. This digestion data validated the β1,4-linkage of N,N′-diacetylchitobiose unit in compound 15.

Solid-Phase Synthesis of the CD52 Peptide Bearing Fucα1-6GlcNAc (17).

The CD52 peptide was synthesized manually by the Fmoc-chemistry using Fmoc-protected amino acid derivatives. An O-link TGT resin (Novabiochem Corp) was used as the solid support, in which the first amino acid (Ser) was attached through the acid-labile ester linkage. To introduce a Fucα1-6GlcNAc residue at the N-glycosylation site, Fmoc-Asn(Ac₅Fucα1-6GlcNAc)-OH (8) was used as building blocks to replace the residues at Asn-3 in the solid-phase peptide synthesis. HATU (0.5 M in DMF) and DIPEA (1.0 M in DMF) (1:1, v/v) were used as the coupling activator and piperidine (20% in DMF) was used as the deblocking reagent. Synthesis was carried out on a 10 μmol scale and 4-fold excess of Fmoc-protected building blocks were used for each coupling reaction cycle. The N-terminus amino group was protected with acetyl group by treatment with Ac₂O/DIPEA. The resulted resin (16) was cleaved by treatment with TFA/CH₂Cl₂ (1/4, v/v) at r.t. for 5 h to release the crude peptide and simultaneously remove the protecting groups of Trt and t-Bu. The Ac groups on the disaccharide were removed by treatment with 5% aqueous hydrazine at rt for 1 h. The residue was subject to preparative HPLC purification to give the peptide CD52-Fucα1-6GlcNAc (17) as a white powder (14.4 mg, overall yield 90%). Analytical HPLC of 17 (Method B): t_(R)=23.8 min; ¹H NMR (D₂O, 400 MHz): δ 4.91 (d, J=9.6 Hz, 1H, H1 of GlcNAc), 4.76 (d, J=3.6 Hz, 1H, H1 of Fuc), 4.71-4.58 (m, 3H, αH of Ser, □H of Asp, □H of Asn), 4.39-4.25 (m, 7H, αH of Ser×3, αH of Pro, αH of Gln×2, αH of Thr), 4.19-4.10 (m, 3H, αH of Thr, αH of Thr×2), 3.99 (q, J=6.8 Hz, 1H, H5 of Fuc), 3.86-3.60 (m, 18H), 3.52-3.38 (m, 3H), 2.82-2.64 (m, 4H, αH of Asn×2, αH of Asp×2), 2.27-2.15 (m, 5H, Gln-H, Pro-H), 2.08-1.82 (m, 13H, Ac, Gln-H, Pro-H), 1.08 (m, 9H, Thr-CH₃×2, Fuc-CH₃); ¹H-¹³C HSQC NMR (¹³C 125 MHz, ¹H 500 MHz, D₂O) δ 4.91/78.4 (GlcNAc-1), 4.76/99.2 (Fuc-1), 4.69/53.1 (Ser-α), 4.68/49.8 (Asp-α), 4.60/49.6 (Asn-α), 4.39/56.1 (Ser-αα), 4.35/61.8 (Pro-α), 4.31/56.3 (Ser-α), 4.30/56.0 (Gln-α), 4.28/53.3 (Gln-α), 4.26/58.9 (Ser-α), 4.25/59.1 (Thr-α), 4.18/53.5 (Thr-α), 4.16/67.8 (Thr-β), 4.13/67.9 (Thr-β), 3.99/67.5 (Fuc-5), 3.85/68.3 (GlcNAc-6), 3.64/68.3 (GlcNAc-6), 2.80/35.8 (Asn-β), 2.74/36.4 (Asp-β), 2.25/31.4 (Gln-β), 2.21/30.7 (Pro), 2.02/22.1 (Ac), 1.95/22.8 (Ac), 1.89/30.6 (Pro), 1.83/27.2 (Ac), 1.10/16.2 (Thr-CH₃), 1.08/19.7 (Fuc-CH₃), 1.06/16.2 (Thr-CH₃); MALDI-TOF MS: Calculated for C₆₁H₉₈N₁₆O₃₄, M=1598.64; found, 1622.32 [M+Na]⁺; ESI-MS: 1599.16 [M+H]⁺, 800.27 [M+2H]²⁺.

Chemoenzymatic Synthesis of Sialylated and Core-Fucosylated Complex-Type Glycoform of CD52 (18).

A mixture of CD52 peptide 17 (2 mg, 1.25 μmol) and sialoglycan oxazoline 12 (5 mg, 2.5 μL) in phosphate buffer (50 mM, pH 7.0, 250 μL) was incubated at 30° C. with Endo-F3 (80 μg) for 1 h. The reaction was quenched with 1% TFA (10 μL) and the residue was subject to preparative RP-HPLC to give CD52-Sia₂Gal₂GlcNAc₂Man₃GlcNAc₂Fuc (18) as a white powder (2.5 mg, 55%). t_(R)=21.5 min (analytical HPLC, method B). ¹H NMR (D₂O, 400 MHz): δ 5.00 (s, 1H, H1 of Man⁴), 4.89 (d, J=9.6 Hz, 1H, H1 of GlcNAc¹), 4.81 (s, 1H, H1 of Man^(4′)), 4.75 (s, 1H, H1 of Fuc), 4.72-4.58 (m, 4H, αH of Ser, H1 of Man³, αH of Asp, αH of Asn), 4.56 (d, J=7.6 Hz, H1 of GlcNAc²), 4.48 (d, J=7.2 Hz, H1 of GlcNAc⁵, H1 of GlcNAc^(5′)), 4.41-4.24 (m, 9H, αH of Ser×3, αH of Pro, αH of Gln×2, H1 of Gal⁶, H1 of Gal^(6′), αH of Thr), 4.18-4.14 (m, 3H, αH of Thr, αH of Thr×2), 4.12 (m, 1H), 4.07 (m, 1H), 3.98 (m, 2H), 3.89-3.35 (m, 82H), 2.87-2.61 (m, 4H, αH of Asn×2, αH of Asp×2), 2.54 (m, 2H, H3_(ax) of Sia×2), 2.27-2.18 (m, 5H, Gln-H, Pro-H), 2.07-1.83 (m, 29H, Ac, Gln-H, Pro-H), 1.60 (t, J=12.0 Hz, 2H, H3_(eq) of Sia×2), 1.07 (m, 9H, Thr-CH₃×2, Fuc-CH₃); ¹H-¹³C HSQC NMR (¹³C 125 MHz, ¹H 500 MHz, D₂O) δ 5.00/99.6 (Man⁴-1), 4.89/78.7 (GlcNAc¹-1), 4.81/97.5 (Man^(4′)-1), 4.75/99.8 (Fuc-1), 4.68/54.4 (Ser-α), 4.66/51.3 (Asp-α), 4.65/101.3 (Man³-1), 4.59/51.5 (Asn-α), 4.56/101.7 (GlcNAc²-1), 4.48/100.1 (GlcNAc⁵-1, GlcNAc^(5′)-1), 4.38/56.3 (Ser-α), 4.35/61.5 (Pro-α), 4.31/56.8 (Ser-α), 4.31/56.3 (Gln-α), 4.30/104.4 (Gal⁶-1, Gal^(6′)-1), 4.27/53.7 (Gln-α), 4.26/59.8 (Ser-α), 4.24/60.1 (Thr-α), 4.18/54.2 (Thr-α), 4.15/67.8 (Thr-β), 4.13/67.8 (Thr-β), 3.98/67.5 (Fuc-5), 2.83/35.8 (Asn-β), 2.74/36.2 (Asp-β), 2.54/40.3 (Sia-3_(ax)), 2.25/31.3 (Gln-β), 2.02/22.3 (Ac), 1.95/22.4 (Ac), 1.87/26.8 (Ac), 1.60/40.3 (Sia-3_(eq)), 1.08/15.9 (Thr-CH₃), 1.07/19.7 (Fuc-CH₃), 1.05/15.9 (Thr-CH₃); ESI-MS: Calculated for C₁₃₇H₂₂₁N₂₁O₉₀, M=3600.34; found 1201.66 [M+3H]³′.

Chemoenzymatic Synthesis of Sialylated and Core-Fucosylated Complex-Type Glycoform of CD52 (18) by Transglycosylation with Endo-F3 Mutant, D126A.

A mixture of CD52 peptide 17 and sialoglycan oxazoline 12 in phosphate buffer (50 mM, pH 7.5) was incubated at 30° C. with Endo-F3 mutant D126A (SEQ ID NO: 6), following the above descripted procedures, giving the transglycosylation product with over 90% yield. The product was isolated by RP-HPLC and characterized as described above.

Endo-F3 Digestion of CD52 Glycopeptide 18.

A solution of 18 (20 μg) in a phosphate butter (50 mM, pH 7.0, 20 μL) was incubated with Endo-F3 (2 μg) at 30° C. for 20 h. The digestion was monitored by RP-HPLC combined with ESI-MS analysis. It was clearly shown that the glycopeptide 18 peak disappeared and a new peak emerged in the same position as CD52-Fucα1,6GlcNAc and was confirmed by the ESI-MS. This digestion experiment validated the α1,4-linkage of N,N′-diacetylchitobiose unit in compound 18.

PNGase F Digestion of CD52 Glycopeptide 18.

A solution of 18 (20 μg) in a phosphate buffer (50 mM, pH 7.5, 20 μL) was incubated at 37° C. with PNGase F (500 U) for 4 h. The reaction mixture was subject to analytic RP-HPLC. The released sialoglycan 19 and Asp-CD52 20 was purified and characterized by ESI-MS (FIG. 11). Sialoglycan 19: analytical HPLC (Method B): t_(R)=17.8 min; ESI-MS: calculated for C₉₀H₁₄₈N₆O₆₆, M=2368.84 Da; found (m/z), 1185.82 [M+2H]²⁺, 1040.41 [M−Sia+2H]²′. Asp-CD52 20: analytical HPLC Method B: t_(R)=24.2 min; ESI-MS: calculated for C₄₇H₇₄N₁₄O₂₆, M=1250.49 Da; found (m/z), 1251.56 [M+H]⁺, 626.38 [M+2H]²⁺.

REFERENCES

The contents of all references cited herein are hereby incorporated by reference herein for all purposes.

-   1. A. Varki, Glycobiology, 1993, 3, 97-130. -   2. R. A. Dwek, Chem. Rev., 1996, 96, 683-720. -   3. A. Helenius and M. Aebi, Science, 2001, 291, 2364-2369. -   4. R. S. Haltiwanger and J. B. Lowe, Annu Rev Biochem, 2004, 73,     491-537. -   5. D. H. Dube and C. R. Bertozzi, Nat Rev Drug Discov, 2005, 4,     477-488. -   6. J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd and R. A.     Dwek, Annu Rev Immunol, 2007, 25, 21-50. -   7. R. A. Dwek, T. D. Butters, F. M. Platt and N. Zitzmann, Nat Rev     Drug Discov, 2002, 1, 65-75. -   8. R. Jefferis, Biotechnol. Prog., 2005, 21, 11-16. -   9. G. Walsh and R. Jefferis, Nat. Biotechnol., 2006, 24, 1241-1252. -   10. Y. Kaneko, F. Nimmerjahn and J. V. Ravetch, Science, 2006, 313,     670-673. -   11. R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N.     Reinhold, J. C. Paulson and J. V. Ravetch, Science, 2008, 320,     373-376. -   12. S. Andre, T. Kozar, S. Kojima, C. Unverzagt and H. J. Gabius,     Biol Chem, 2009, 390, 557-565. -   13. S. Andre, T. Kozar, R. Schuberth, C. Unverzagt, S. Kojima     and H. J. Gabius, Biochemistry, 2007, 46, 6984-6995. -   14. C. Unverzagt, S. Andre, J. Seifert, S. Kojima, C. Fink, G.     Srikrishna, H. Freeze, K. Kayser and H. J. Gabius, J Med Chem, 2002,     45, 478-491. -   15. R. Niwa, E. Shoji-Hosaka, M. Sakurada, T. Shinkawa, K.     Uchida, K. Nakamura, K. Matsushima, R. Ueda, N. Hanai and K.     Shitara, Cancer Res, 2004, 64, 2127-2133. -   16. T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y.     Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, N.     Hanai and K. Shitara, J Biol Chem, 2003, 278, 3466-3473. -   17. R. L. Shields, J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G.     Meng, S. H. Weikert and L. G. Presta, J Biol Chem, 2002, 277,     26733-26740. -   18. S. Barrabes, L. Pages-Pons, C. M. Radcliffe, G. Tabares, E.     Fort, L. Royle, D. J. Harvey, M. Moenner, R. A. Dwek, P. M. Rudd, R.     De Llorens and R. Peracaula, Glycobiology, 2007, 17, 388-400. -   19. M. Takahashi, Y. Kuroki, K. Ohtsubo and N. Taniguchi, Carbohydr     Res, 2009, 344, 1387-1390. -   20. D. Osumi, M. Takahashi, E. Miyoshi, S. Yokoe, S. H. Lee, K.     Noda, S, Nakamori, J. Gu, Y. Ikeda, Y. Kuroki, K. Sengoku, M.     Ishikawa and N. Taniguchi, Cancer Sci, 2009, 100, 888-895. -   21. M. A. Comunale, M. Wang, J. Hafner, J. Krakover, L. Rodemich, B.     Kopenhaver, R. E. Long, O. Junaidi, A. M. Bisceglie, T. M. Block     and A. S. Mehta, J Proteome Res, 2009, 8, 595-602. -   22. M. J. Grogan, M. R. Pratt, L. A. Marcaurelle and C. R. Bertozzi,     Annu. Rev. Biochem., 2002, 71, 593-634. -   23. T. Buskas, S. Ingale and G. J. Boons, Glycobiology, 2006, 16,     113R-136R. -   24. C. S. Bennett and C. H. Wong, Chem. Soc. Rev., 2007, 36,     1227-1238. -   25. D. P. Gamblin, E. M. Scanlan and B. G. Davis, Chem. Rev., 2009,     109, 131-163. -   26. G. J. Bernardes, B. Castagner and P. H. Seeberger, ACS Chem     Biol, 2009, 4, 703-713. -   27. J. R. Rich and S. G. Withers, Nat Chem Biol, 2009, 5, 206-215. -   28. D. Macmillan and C. R. Bertozzi, Angew. Chem. Int. Ed., 2004,     43, 1355-1359. -   29. N. Yamamoto, Y. Tanabe, R. Okamoto, P. E. Dawson and Y.     Kajihara, J. Am. Chem. Soc., 2008, 130, 501-510. -   30. C. Piontek, P. Ring, O. Harjes, C. Heinlein, S. Mezzato, N.     Lombana, C. Pohner, M. Puttner, D. Varon Silva, A. Martin, F. X.     Schmid and C. Unverzagt, Angew. Chem. Int. Ed., 2009, 48, 1936-1940. -   31. C. Piontek, D. Varon Silva, C. Heinlein, C. Pohner, S.     Mezzato, P. Ring, A. Martin, F. X. Schmid and C. Unverzagt, Angew.     Chem. Int. Ed., 2009, 48, 1941-1945. -   32. S. I. van Kasteren, H. B. Kramer, H. H. Jensen, S. J.     Campbell, J. Kirkpatrick, N.J. Oldham, D. C. Anthony and B. G.     Davis, Nature, 2007, 446, 1105-1109. -   33. K. Hirano, D. Macmillan, K. Tezuka, T. Tsuji and Y. Kajihara,     Angew. Chem. Int. Ed., 2009, 48, 9557-9560. -   34. S. R. Hamilton, P. Bobrowicz, B. Bobrowicz, R. C. Davidson, H.     Li, T. Mitchell, J. H. Nett, S. Rausch, T. A. Stadheim, H.     Wischnewski, S. Wildt and T. U. Gerngross, Science, 2003, 301,     1244-1246. -   35. S. Wildt and T. U. Gerngross, Nat. Rev. Microbiol., 2005, 3,     119-128. -   36. S. R. Hamilton, R. C. Davidson, N. Sethuraman, J. H. Nett, Y.     Jiang, S. Rios, P. Bobrowicz, T. A. Stadheim, H. Li, B. K. Choi, D.     Hopkins, H. Wischnewski, J. Roser, T. Mitchell, R. R.     Strawbridge, J. Hoopes, S. Wildt and T. U. Gerngross, Science, 2006,     313, 1441-1443. -   37. S. Eller, R. Schuberth, G. Gundel, J. Seifert and C. Unverzagt,     Angew. Chem. Int. Ed., 2007, 46, 4173-4175. -   38. B. Sun, B. Srinivasan and X. Huang, Chemistry, 2008, 14,     7072-7081. -   39. K. Yamamoto, J. Biosci. Bioeng., 2001, 92, 493-501. -   40. L. X. Wang, Carbohydr. Res., 2008, 343, 1509-1522. -   41. L. X. Wang and W. Huang, Curr Opin Chem Biol, 2009, 13, 592-600. -   42. B. Li, Y. Zeng, S. Hauser, H. Song and L. X. Wang, J Am Chem     Soc, 2005, 127, 9692-9693. -   43. H. Li, B. Li, H. Song, L. Breydo, I. V. Baskakov and L. X.     Wang, J. Org. Chem., 2005, 70, 9990-9996. -   44. B. Li, H. Song, S. Hauser and L. X. Wang, Org Lett, 2006, 8,     3081-3084. -   45. Y. Zeng, J. Wang, B. Li, S. Hauser, H. Li and L. X. Wang, Chem.     Eur. J., 2006, 12, 3355-3364. -   46. Y. Wei, C. Li, W. Huang, B. Li, S. Strome and L. X. Wang,     Biochemistry, 2008, 47, 10294-10304. -   47. H. Ochiai, W. Huang and L. X. Wang, J Am Chem Soc, 2008, 130,     13790-13803. -   48. T. W. Rising, T. D. Claridge, J. W. Moir and A. J. Fairbanks,     ChemBioChem, 2006, 7, 1177-1180. -   49. T. W. Rising, T. D. Claridge, N. Davies, D. P. Gamblin, J. W.     Moir and A. J. Fairbanks, Carbohydr Res, 2006, 341, 1574-1596. -   50. T. W. Rising, C. D. Heidecke, J. W. Moir, Z. Ling and A. J.     Fairbanks, Chem. Eur. J., 2008, 14, 6444-6464. -   51. T. B. Parsons, J. W. Moir and A. J. Fairbanks, Org. Biomol.     Chem., 2009, 7, 3128-3140. -   52. M. Umekawa, W. Huang, B. Li, K. Fujita, H. Ashida, L. X. Wang     and K. Yamamoto, J Biol Chem, 2008, 283, 4469-4479. -   53. C. D. Heidecke, Z. Ling, N. C. Bruce, J. W. Moir, T. B. Parsons     and A. J. Fairbanks, Chembiochem, 2008, 9, 2045-2051. -   54. W. Huang, C. Li, B. Li, M. Umekawa, K. Yamamoto, X. Zhang     and L. X. Wang, J Am Chem Soc, 2009, 131, 2214-2223. -   55. M. Umekawa, C. Li, T. Higashiyama, W. Huang, H. Ashida, K.     Yamamoto and L. X. Wang, J Biol Chem, 2010, 285, 511-521. -   56. W. Huang, Q. Yang, M. Umekawa, K. Yamamoto and L. X. Wang,     Chembiochem, 2010, 11, 1350-1355. -   57. P. Kirsch, N. Kusunose, J. Aikawa, T. Kigawa, S. Yokoyama and T.     Ogawa, Bioorg Med Chem, 1995, 3, 1631-1636. -   58. T. Uchiyama and O. Hindsgaul, Synlett, 1996, 499-501. -   59. K. Takegawa, K. Yamabe, K. Fujita, M. Tabuchi, M. Mita, H.     Izu, A. Watanabe, Y. Asada, M. Sano, A. Kondo, I. Kato and S.     Iwahara, Arch. Biochem. Biophys., 1997, 338, 22-28. -   60. K. Yamamoto, S. Kadowaki, M. Fujisaki, H. Kumagai and T.     Tochikura, Biosci Biotechnol Biochem, 1994, 58, 72-77. -   61. R. B. Trimble, P. H. Atkinson, A. L. Tarentino, T. H. Plummer,     Jr., F. Maley and K. B. Tomer, J Biol Chem, 1986, 261, 12000-12005. -   62. T. B. Parsons, M. K. Patel, A. B. Boraston, D. J. Vocadlo     and A. J. Fairbanks, Org Biomol Chem, 2010, 8, 1861-1869. -   63. H. Muramatsu, H. Tachikui, H. Ushida, X. Song, Y. Qiu, S.     Yamamoto and T. Muramatsu, Journal of Biochemistry, 2001, 129,     923-928. -   64. A. Treumann, M. R. Lifely, P. Schneider and M. A. Ferguson, J     Biol Chem, 1995, 270, 6088-6099. -   65. S. Schroter, P. Den, H. S. Conradt, M. Nimtz, G. Hale and C.     Kirchhoff, J Biol Chem, 1999, 274, 29862-29873. -   66. A. Domagala and M. Kurpisz, Med Sci Monit, 2001, 7, 325-331. -   67. N. Shao, J. Xue and Z. Guo, J. Org. Chem., 2003, 68, 9003-9011. -   68. N. Shao, J. Xue and Z. Guo, Angew. Chem. Int. Ed., 2004, 43,     1569-1573. -   69. M. R. Pratt and C. R. Bertozzi, J. Am. Chem. Soc., 2003, 125,     6149-6159. -   70. H. Li, S. Singh, Y. Zeng, H. Song and L. X. Wang, Bioorg. Med.     Chem. Lett., 2005, 15, 895-898. -   71. K. Haneda, T. Inazu, K. Yamamoto, H. Kumagai, Y. Nakahara and A.     Kobata, Carbohydr. Res., 1996, 292, 61-70. -   72. K. Fujita, N. Tanaka, M. Sano, I. Kato, Y. Asada and K.     Takegawa, Biochem. Biophys. Res. Commun., 2000, 267, 134-138. -   73. V. Rao, C. Guan, P. Van Roey, Structure 1995, 3, 449-457. -   R. B. Trimble, A. L. Tarentino, J. Biol. Chem. 1991, 266, 1646-1651. -   A. L. Tarentino, T. H. Plummer, Jr., Methods Enzymol. 1994, 230,     44-57. -   A. Reddy, B. G. Grimwood, T. H. Plummer, A. L. Tarentino,     Glycobiology 1998, 8, 633-636. -   A. L. Tarentino, G. Quinones, T. H. Plummer, Jr., Glycobiology 1995,     5, 599-601. -   T. H. Plummer, Jr., A. W. Phelan, A. L. Tarentino, Anal. Biochem.     1996, 235, 98-101. -   C. A. Waddling, T. H. Plummer, Jr., A. L. Tarentino, P. Van Roey,     Biochemistry 2000, 39, 7878-7885. -   I. Tews, A. C. Terwisscha van Schelting a, A. Perrakis, K. S.     Wilson, B. W. Dijkstra, J. Am. Chem. Soc. 1997, 119, 7954-7959. -   K. A. Brameld, W. D. Shrader, B. Imperiali, W. A. Goddard, 3rd, J.     Mol. Biol. 1998, 280, 913-923. -   W. Huang, X. Zhang, T. Ju, R. D. Cummings, L. X. Wang, Org. Biomol.     Chem. 2010, 8, 5224-5233. -   P. Kuhn, A. L. Tarentino, T. H. Plummer, Jr., P. Van Roey,     Biochemistry 1994, 33, 11699-11706. -   A. L. Tarentino, G. Quinones, A. Trumble, L. M. Changchien, B.     Duceman, F. Maley, T. H. Plummer, Jr., J. Biol. Chem. 1990, 265,     6961-6966. -   Tarentino, A. L., Quinones, G., Changchien, L. M. and Plummer, T. H.     Jr., J. Biol. Chem., 268 (13), 9702-9708 (1993). -   Camilli, R., Del Grosso, M., Iannelli, F. and Pantosti, A.,     Antimicrob. Agents Chemother. 52 (2), 619-625 (2008)] -   Raju, T. S., and Scallon, B. J. (2006) Biochem. Biophys. Res.     Commun. 341, 797-803. -   Abbott, D. W., Macauley, M. S., Vocadlo, D. J., and     Boraston, A. B. (2009) J. Biol. Chem. 284, 11676-11689. 

1. A method of preparing a core-fucosylated glycopeptide or glycoprotein having a predetermined oligosaccharide moiety, the method comprising: providing a core-fucosylated acceptor glycopeptide or glycoprotein comprising an asparagine-linked N-acetylglucosamine (GlcNAc) residue linked to a core fucose residue; and enzymatically reacting the core-fucosylated acceptor glycoprotein or glycopeptide with an activated oligosaccharide donor in the presence of at least one endoglycosidase selected from the group consisting of Endoglycosidase-F2, Endoglycosidase-F2 D124A mutant, Endoglycosidase-F2 D124Q mutant, Endoglycosidase-F3, Endoglycosidase-F3 D126A mutant, Endoglycosidase-F3 D126Q mutant and Endoglycosidase-D N322Q mutant, wherein the activated oligosaccharide donor carries an oligosaccharide moiety comprising a predetermined number and type of sugar residues, such that, via enzymatic reaction, the activated oligosaccharide moiety is covalently linked to the acceptor glycoprotein or glycopeptide; thereby preparing the core-fucosylated glycoprotein or glycopeptide having the predetermined oligosaccharide moiety.
 2. The method of claim 1, wherein the core-fucosylated acceptor glycopeptide or glycoprotein is an antibody or fragment thereof.
 3. The method of claim 1, wherein the activated oligosaccharide component is a synthetic oligosaccharide oxazoline.
 4. The method of claim 3, wherein the synthetic oligosaccharide oxazoline is a di-, tri-, tetra-, penta-, hexyl-, hepta-, octyl-, nona-, deca-, or undeca-saccharide oxazoline.
 5. The method of claim 3, wherein the synthetic oligosaccharide oxazoline further comprises an additional biologically active agent or a tag.
 6. The method of claim 5, wherein the additional biologically active agent or tag is a drug, toxin, fluorescent probe, biotin, a PEG, lipid, or polypeptide.
 7. The method of claim 1, wherein the core-fucosylated acceptor glycopeptide or glycoprotein is an alpha-1-6-fucosyl-GlcNAc-peptide or an alpha-1-6-fucosyl-GlcNAc-protein.
 8. The method of claim 2, wherein the antibody is a monoclonal antibody selected from the group consisting of 17b, 48d, A32, C11, 2G12, F240, IgG1b12, 19e, X5, TNX-355, cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, nimotuzumab, ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab, mepolizumab and MYO-029.
 9. The method of claim 1, wherein the step of providing an acceptor fucosylated glycopeptide or glycoprotein comprises (a) providing a core-fucosylated glycopeptide or glycoprotein substrate comprising at least two GlcNAc residues in a chain positioned next to the protein or peptide; and (b) treating the core-fucosylated glycopeptide or glycoprotein substrate with an endo-enzyme to hydrolyze the bond between the two GlcNAc residues positioned closest to the peptide thereby forming a deglycosylated peptide or protein carrying the fucosylated GlcNAc containing glycopeptide or glycoprotein having a single GlcNAc-moiety.
 10. The method of claim 2, wherein the antibody further comprises an additional moiety selected from a group consisting of a therapeutic agent for treating cancer, a therapeutic agent for HIV; a toxin, an antibody different from the modified antibody which is reactive to another receptor, an antigen, a chemokine and a cytokine.
 11. The method of claim 1, wherein Endoglycosidase-F2 comprises SEQ ID NO: 2 or a sequence having 95% homology thereof, Endoglycosidase-F2 D124A mutant comprises SEQ ID N: 4, Endoglycosidase-F2 D124Q mutant comprises SEQ ID NO: 5, Endoglycosidase-F3 comprises SEQ ID NO 3 or a sequence having 95% homology thereof, Endoglycosidase-F3 D126A mutant comprising SEQ ID NO: 6, Endoglycosidase-F3 D126Q mutant comprising SEQ ID NO: 7 and Endoglycosidase-D N322Q mutant comprising SEQ ID NO: 9, wherein the sequences having 95% homology also exhibit transglycosylating ability on a core-fucosylated GlcNAc containing glycopeptide or glycoprotein.
 12. The method of claim 11, wherein a sequence having at least 95% identity to Endo-F3 and is effective for transglycosylation is selected from the group consisting of D126R, D126N, D126C, D126E, D126G, D126H, D1261, D126L, D126K, D126M, D126F, D126P, D126S, D126T, D126W, D126Y and D126V.
 13. A method of synthesizing a homogeneous core-fucosylated glycoprotein, the method comprising: (a) providing a core-fucosylated glycoprotein or glycopeptides comprising a heterogeneous N-glycans; (b) removing the heterogeneous N-glycans by an enzyme selected from the group Endo-H or Endo-A to form homogeneous core-fucosylated GlcNAc-containing proteins; (c) providing an oligosaccharide containing oxazoline with a desired oligosaccharide component comprising a N-glycan having a defined number and type of sugar residues; (d) enzymatically transglycosylating the core-fucosylated GlcNAc-containing protein or peptide with the sugar containing oxazoline using an endoglycosidase (ENGase) selected from the group consisting of Endo-F2, Endo-F3, Endo-D and mutants thereof, thereby forming homogeneous core-fucosylated glycoproteins having the defined number and type of sugar residues.
 14. The method of claim 13, wherein the oligosaccharide containing oxazoline is a di-, tri-, tetra-, penta-, hexyl-, hepta-, octyl-, nona-, deca-, or undeca-saccharide oxazoline.
 15. The method of claim 13, wherein the core-fucosylated GlcNAc containing protein is an alpha-1-6-fucosyl-GlcNAc-protein.
 16. A method of synthesizing a modified antibody or fragment thereof, the method comprising; providing an antibody comprising a fucosylated N-acetylglucosamine (GlcNAc) moiety to form GlcNAc-peptide acceptor; wherein the fucosylated N-acetylglucosamine (GlcNAc) moiety is positioned on the Fc region of the antibody; transglycosylating an oligosaccharide oxazoline having a predetermined number of saccharides and the GlcNAc-peptide acceptor under the catalysis of an endoglycosidase (ENGase) enzyme to form the modified antibody with the predetermined number of saccharides.
 17. The method of claim 16, wherein the modified antibody further comprises an additional moiety including, a therapeutic agent for treating cancer, a therapeutic agent for HIV; a toxin, an antibody different from the modified antibody which is reactive to another receptor, an antigen, a therapeutic polypeptide, a chemokine and/or a cytokine attached to the oligosaccharide oxazoline.
 18. A delivery device for delivering a drug having biological activity to treat a condition, the delivery device comprising: a remodel antibody comprising a recombinant core-fucosylated IgG-Fc antibody having a predetermined number of sugar residues and a drug attached to a terminal sugar.
 19. The delivery device of claim 18, wherein the remodel antibody is a monoclonal antibody selected from the group consisting of 17b, 48d, A32, C11, 2G12, F240, IgG1b12, 19e, X5, TNX-355, cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, nimotuzumab, ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab, mepolizumab and MYO-029. 